








## INTERNATIONAL APPLICATION PUBLISHED UNDER

(51) International Patent Classification <sup>6</sup> : C07D 239/42, 401/04, 409/14, A61K 31/505, 31/38		A1	(11) International Publication Number: <b>WO 9605177</b>
			(43) International Publication Date: 22 February 1996 (22.02.96)
(21) International Application Number: PCT/KR95/00105			440-150 (KR). LEE, Sang, Ho [KR/KR]; #1-5, Seosung-dong, Happo-gu, Masan-si, Kyongsangnam-do 631-430 (KR).
(22) International Filing Date: 10 August 1995 (10.08.95)			(74) Agent: JANG, Seong, Ku; 275, Yangjae-dong, Seocho-gu, Seoul 137-130 (KR).
(30) Priority Data: 199419997 13 August 1994 (13.08.94) KR 199419998 13 August 1994 (13.08.94) KR			(81) Designated States: AU, CA, CN, JP, RU, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).
(71) Applicant (for all designated States except US): YUHAN CORPORATION [KR/KR]; #49-6, Taebang-dong, Tongjak-gu, Seoul 156-020 (KR).			
(72) Inventors; and (75) Inventors/Applicants (for US only): LEE, Jong, Wook [KR/KR]; #50-5, Byulyang-dong, Kwacheon-si, Kyonggi-do 427-040 (KR). CHAE, Jeong, Seok [KR/KR]; #10-144, Shillim-dong, Kwanak-gu, Seoul 151-010 (KR). KIM, Chang, Seop [KR/KR]; #834-12, Bono-dong, Ansan-si, Kyonggi-do 425-180 (KR). KIM, Jae, Kyu [KR/KR]; 308-101, Jukong Apartment, #17, Byulyang-dong, Kwacheon-si, Kyonggi-do 427-040 (KR). LIM, Dae, Sung [KR/KR]; #938-13, Sihung-3-dong, Kuro-gu, Seoul 152-033 (KR). SHON, Moon, Kyu [KR/KR]; #San 182-4-3, Bisan-dong, Dongan-ku, Anyang-si, Kyonggi-do 430-050 (KR). CHOI, Yeon, Shik [KR/KR]; 2-911, Youngkwang Apartment, #220-4, Hwasu-dong, Jangan-gu, Suwon-si, Kyonggi-do			Published With international search report.

(54) Title: NOVEL PYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF

## (57) Abstract

The present invention relates to novel pyrimidine derivatives of formulae (I-1) and (I-2) and pharmaceutically acceptable salts thereof which possess an excellent anti-secretory activity, pharmaceutical compositions containing same as an active ingredient, their novel intermediates, and processes for the preparation thereof. In said formulae, R<sub>4</sub> and R<sub>5</sub>, which may be the same or different, are independently hydrogen or a C<sub>1</sub>-C<sub>3</sub> alkyl group, or jointly form a cyclopentyl or cyclohexyl ring; A is a group of formula (II) wherein R<sub>1</sub> and R<sub>2</sub> are, independently of each other, hydrogen or a C<sub>1</sub>-C<sub>3</sub> alkyl group, and R<sub>3</sub> is hydrogen, a C<sub>1</sub>-C<sub>3</sub> alkyl group or a halogen; and B is 1-(substituted)-1,2,3,4-tetrahydroisoquinolin-2-yl of formula (III-1) or 7-(substituted)-4,5,6,7-tetrahydrothieno[2,3-c]pyridin-6-yl of formula (III-2) wherein R<sub>6</sub> is hydrogen or a C<sub>1</sub>-C<sub>3</sub> alkyl group.



BEST AVAILABLE COPY

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LJ	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

**NOVEL PYRIMIDINE DERIVATIVES AND  
PROCESSES FOR THE PREPARATION THEREOF**

**5 Field of the Invention**

The present invention relates to novel pyrimidine derivatives and pharmaceutically acceptable salts thereof which possess an excellent anti-secretory activity, 10 pharmaceutical compositions containing same as an active ingredient, their novel intermediates, and processes for the preparation thereof.

**15 Background of the Invention**

For the treatment of peptic ulcer disease, various drugs such as antacid, anticholinergic agent,  $H_2$ -receptor antagonist and proton pump inhibitor have been used. 20 Recently, the advent of omeprazole useful as a proton pump inhibitor has rekindled research activities in this field.

However, it has been pointed out that the proton pump inhibition by omeprazole is irreversible, which may induce side effects. Accordingly, various attempts to develop a 25 reversible proton pump inhibitor are being actively made. For example, European Patent Nos. 322133 and 404322 disclose quinazoline derivatives, European Patent No. 259174 describes quinoline derivatives, and WO 91/13337 offers pyrimidine derivatives, as a reversible proton pump 30 inhibitor. Further, the present inventors have also reported quinazoline derivatives in WO 94/14795.

**Summary of the Invention**

35

The present inventors have carried out extensive research to develop a reversible proton pump inhibitor with

- 2 -

improved efficacy; and, as a result, have discovered that pyrimidine derivatives having a tetrahydroisoquinoline group at the 2- or 4-position of the pyrimidine nucleus exhibit excellent proton pump inhibition effects and possess the 5 ability to attain a reversible proton pump inhibition.

Accordingly, it is a primary object of the present invention to provide novel pyrimidine derivatives having a tetrahydroisoquinoline group at the 2- or 4-position of the pyrimidine nucleus, and pharmaceutically acceptable salts 10 thereof.

It is another object of the present invention to provide processes for preparing said compounds.

It is a further object of the present invention to provide pharmaceutical compositions containing same as 15 active ingredients.


It is still another object of the invention to provide novel intermediate compounds useful for the preparation of the novel pyrimidine derivatives.

20


Detailed Description of the Invention

In accordance with the present invention, there are provided novel pyrimidine derivative compounds of formulae 25 (I-1) and (I-2) inclusive of pharmaceutically acceptable salts thereof:

30



(I-1)



(I-2)


wherein:

35 R<sub>4</sub> and R<sub>5</sub>, which may be the same or different, are independently hydrogen or a C<sub>1</sub>-C<sub>3</sub> alkyl group, or jointly form a cyclopentyl or cyclohexyl ring;

- 3 -

A is a group of formula(II):


5




wherein R<sub>1</sub> and R<sub>2</sub> are, independently of each other, hydrogen or a C<sub>1</sub>-C<sub>3</sub> alkyl group, and R<sub>3</sub> is hydrogen, a C<sub>1</sub>-C<sub>3</sub> alkyl group or a halogen; and

10 B is 1-(substituted)-1,2,3,4-tetrahydroisoquinolin-2-yl of formula (III-1) or 7-(substituted)-4,5,6,7-tetrahydrothieno[2,3-c]pyridin-6-yl of formula (III-2)

15



(III-1)



(III-2)

20

wherein R<sub>6</sub> is hydrogen or a C<sub>1</sub>-C<sub>3</sub> alkyl group.

25

Among the compounds of the present invention, preferred are those wherein: R<sub>1</sub>, R<sub>2</sub> and R<sub>6</sub> are independently hydrogen or a methyl group; R<sub>3</sub> is hydrogen or a fluorine; and R<sub>4</sub> and R<sub>5</sub>, which may be the same or different, are independently hydrogen or a C<sub>1</sub>-C<sub>3</sub> alkyl group, or jointly form a cyclopentyl or cyclohexyl ring.

30

Particularly, preferred compounds of the present invention are:

2-(2-methyl-4-fluorophenylamino)-4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride;

6-methyl-2-(2-methyl-4-fluorophenylamino)-4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride;

35

6-methyl-4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)-2-(4-fluorophenylamino)pyrimidine hydrochloride;

6-methyl-2-(N-methylphenylamino)-4-(1-methyl-1,2,3,4-tetra-

- 4 -

hydroisoquinolin-2-yl)pyrimidine hydrochloride;  
6-ethyl-2-(2-methyl-4-fluorophenylamino)-4-(1-methyl-1,2,  
3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride;  
6-ethyl-2-(4-fluorophenylamino)-4-(1-methyl-1,2,3,4-tetra-  
5 hydroisoquinolin-2-yl)pyrimidine hydrochloride;  
6-ethyl-2-(N-methylphenylamino)-4-(1-methyl-1,2,3,4-tetra-  
hydroisoquinolin-2-yl)pyrimidine hydrochloride;  
6-ethyl-2-(2-methylphenylamino)-4-(1-methyl-1,2,3,4-tetra-  
hydroisoquinolin-2-yl)pyrimidine hydrochloride;  
10 2-(2-methyl-4-fluorophenylamino)-4-(1-methyl-1,2,3,4-tetra-  
hydroisoquinolin-2-yl)-6-propylpyrimidine hydrochloride;  
4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)-6-propyl-  
2-(4-fluorophenylamino)pyrimidine hydrochloride;  
2-(N-methylphenylamino)-4-(1-methyl-1,2,3,4-tetrahydroiso-  
15 quinolin-2-yl)-6-propylpyrimidine hydrochloride;  
5,6-dimethyl-2-(2-methyl-4-fluorophenylamino)-4-(1-methyl-  
1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride;  
(R)-5,6-dimethyl-2-(2-methyl-4-fluorophenylamino)-4-(1-  
methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine  
20 hydrochloride;  
(S)-5,6-dimethyl-2-(2-methyl-4-fluorophenylamino)-4-(1-  
methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine  
hydrochloride;  
5,6-dimethyl-2-(4-fluorophenylamino)-4-(1-methyl-1,2,3,4-  
25 tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride;  
(R)-5,6-dimethyl-2-(4-fluorophenylamino)-4-(1-methyl-1,2,  
3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride;  
(S)-5,6-dimethyl-2-(4-fluorophenylamino)-4-(1-methyl-1,2,  
3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride;  
30 5,6-dimethyl-2-(N-methylphenylamino)-4-(1-methyl-1,2,3,4-  
tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride;  
(R)-5,6-dimethyl-2-(N-methylphenylamino)-4-(1-methyl-1,2,  
3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride;  
(S)-5,6-dimethyl-2-(N-methylphenylamino)-4-(1-methyl-1,2,  
35 3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride;  
5,6-dimethyl-2-(phenylamino)-4-(1-methyl-1,2,3,4-tetra-  
hydroisoquinolin-2-yl)pyrimidine hydrochloride;

- 5 -

(R)-5,6-dimethyl-2-(4-phenylamino)-4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride;  
(S)-5,6-dimethyl-2-(4-fluorophenylamino)-4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride;  
5 5,6-dimethyl-2-(2-methylphenylamino)-4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride;  
5,6-dimethyl-2-(4-methylphenylamino)-4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride;  
5-methyl-6-ethyl-2-(2-methyl-4-fluorophenylamino)-4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride;  
10 5-methyl-6-ethyl-2-(4-fluorophenylamino)-4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride;  
5-methyl-6-ethyl-2-(N-methylphenylamino)-4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride;  
15 3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride;  
2-(2-methyl-4-fluorophenylamino)-4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)cyclopenta[d]pyrimidine hydrochloride;  
2-(4-fluorophenylamino)-4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)cyclopenta[d]pyrimidine hydrochloride;  
20 2-(N-methylphenylamino)-4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)cyclopenta[d]pyrimidine hydrochloride;  
2-(2-methyl-4-fluorophenylamino)-4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)-5,6,7,8-tetrahydroquinazoline hydrochloride;  
25 2-(N-methylphenylamino)-4-(1-methyl-1,2,3,4-tetrahydroisoquinoline-2-yl)-5,6,7,8-tetrahydroquinazoline hydrochloride;  
6-methyl-2-(2-methyl-4-fluorophenylamino)-4-(1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride;  
6-methyl-2-(4-fluorophenylamino)-4-(1,2,3,4-tetrahydroisoquinoline-2-yl)pyrimidine hydrochloride;  
30 6-methyl-2-(N-methylphenylamino)-4-(1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride;  
6-ethyl-2-(2-methyl-4-fluorophenylamino)-4-(1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride;  
35 6-ethyl-2-(4-fluorophenylamino)-4-(1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride;  
6-ethyl-2-(N-methylphenylamino)-4-(1,2,3,4-tetrahydroiso-

- 6 -

quinolin-2-yl)pyrimidine hydrochloride;  
6-ethyl-2-(2-methylphenylamino)-4-(1,2,3,4-tetrahydroiso-  
quinolin-2-yl)pyrimidine hydrochloride;  
5,6-dimethyl-2-(2-methyl-4-fluorophenylamino)-4-(1,2,3,4-  
5 tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride;  
5,6-dimethyl-2-(4-fluorophenylamino)-4-(1,2,3,4-tetrahydro-  
isoquinolin-2-yl)pyrimidine hydrochloride;  
5,6-dimethyl-2-(N-methylphenylamino)-4-(1,2,3,4-tetrahydro-  
isoquinolin-2-yl)pyrimidine hydrochloride;  
10 5-methyl-6-ethyl-2-(2-methyl-4-fluorophenylamino)-4-(1,2,  
3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride;  
5-methyl-6-ethyl-2-(4-fluorophenylamino)-4-(1,2,3,4-tetra-  
hydroisoquinolin-2-yl)pyrimidine hydrochloride;  
5-methyl-6-ethyl-2-(N-methylphenylamino)-4-(1,2,3,4-tetra-  
15 hydroisoquinolin-2-yl)pyrimidine hydrochloride;  
2-(2-methyl-4-fluorophenylamino)-4-(1,2,3,4-tetrahydroiso-  
quinolin-2-yl)cyclopenta[d]pyrimidine hydrochloride;  
2-(2-methyl-4-fluorophenylamino)-4-(1,2,3,4-tetrahydroiso-  
quinolin-2-yl)-5,6,7,8-tetrahydroquinazolinehydrochloride;  
20 2-(4-fluorophenylamino)-4-(1,2,3,4-tetrahydroisoquinolin-  
2-yl)-5,6,7,8-tetrahydroquinazoline hydrochloride;  
2-(N-methylphenylamino)-4-(1,2,3,4-tetrahydroisoquinolin-  
2-yl)-5,6,7,8-tetrahydroquinazoline hydrochloride;  
2-(2-methylphenylamino)-4-(1,2,3,4-tetrahydroisoquinolin-  
25 2-yl)-5,6,7,8-tetrahydroquinazoline hydrochloride;  
6-methyl-2-(2-methyl-4-fluorophenylamino)-4-(7-methyl-4,5,  
6,7-tetrahydrothieno[2,3-c]pyridin-6-yl)pyrimidine  
hydrochloride;  
6-methyl-4-(7-methyl-4,5,6,7-tetrahydrothieno[2,3-c]-  
30 pyridin-6-yl)-2-(4-fluorophenylamino)pyrimidine  
hydrochloride;  
6-methyl-2-(N-methylphenylamino)-4-(7-methyl-4,5,6,7-tetra-  
hydrothieno[2,3-c]pyridin-6-yl)pyrimidine hydrochloride;  
5,6-dimethyl-2-(2-methyl-4-fluorophenylamino)-4-(7-methyl-  
35 4,5,6,7-tetrahydrothieno[2,3-c]pyridin-6-yl)pyrimidine  
hydrochloride;  
5-methyl-2-(2-methyl-4-fluorophenylamino)-4-(7-methyl-4,5,

6,7-tetrahydrothieno[2,3-c]pyridin-6-yl)-6-ethylpyrimidine hydrochloride;

6-methyl-4-(2-methyl-4-fluorophenylamino)-2-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride;

5 6-methyl-4-(4-fluorophenylamino)-2-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride;

6-methyl-4-(2-methyl-4-fluorophenylamino)-2-(7-methyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridin-6-yl)pyrimidine hydrochloride;

10 6-ethyl-2-(2-methyl-4-fluorophenylamino)-4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride;

6-ethyl-4-(2-methyl-4-fluorophenylamino)-2-(1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride;

15 6-ethyl-4-(4-fluorophenylamino)-2-(1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride;

6-ethyl-4-(N-methylphenylamino)-2-(1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride;

20 5,6-dimethyl-4-(2-methyl-4-fluorophenylamino)-2-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride;

(R)-5,6-dimethyl-4-(2-methyl-4-fluorophenylamino)-2-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride;

25 (S)-5,6-dimethyl-4-(2-methyl-4-fluorophenylamino)-2-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride;

5,6-dimethyl-4-(4-fluorophenylamino)-2-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride;

30 (R)-5,6-dimethyl-4-(4-fluorophenylamino)-2-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride;

(S)-5,6-dimethyl-4-(4-fluorophenylamino)-2-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride;

5,6-dimethyl-4-(N-methylphenylamino)-2-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride;

35 (R)-5,6-dimethyl-4-(N-methylphenylamino)-2-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride;

- 8 -

(S)-5,6-dimethyl-4-(N-methylphenylamino)-2-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride;

5,6-dimethyl-4-(2-methyl-4-fluorophenylamino)-2-(1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride;

5,6-dimethyl-4-(4-fluorophenylamino)-2-(1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride;

5,6-dimethyl-4-(N-methylphenylamino)-2-(1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride;

5,6-dimethyl-4-(2-methyl-4-fluorophenylamino)-2-(7-methyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridin-6-yl)pyrimidine hydrochloride;

5,6-dimethyl-2-(7-methyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridin-6-yl)-4-(4-fluorophenylamino)pyrimidine hydrochloride;

5,6-dimethyl-4-(N-methylphenylamino)-2-(7-methyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridin-6-yl)pyrimidine hydrochloride;

5-methyl-6-ethyl-4-(2-methyl-4-fluorophenylamino)-2-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride;

4-(2-methyl-4-fluorophenylamino)-2-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)cyclopenta[d]pyrimidine hydrochloride;

2-(2-methyl-4-fluorophenylamino)-4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)-5,6,7,8-tetrahydroquinazoline hydrochloride; and


4-(2-methyl-4-fluorophenylamino)-2-(1,2,3,4-tetrahydroisoquinolin-2-yl)-5,6,7,8-tetrahydroquinazoline hydrochloride.

The pyrimidine derivatives of formulae (I-1) and (I-2) in the present invention may exist in the form of an optical isomer, (R) or (S), or a mixture thereof. Both types of the isomeric compounds are found to exhibit excellent anti-secretory activity.

The compounds of formulae (I-1) and (I-2) may be prepared in accordance with Scheme 1 and Scheme 2, respectively, described below.

- 9 -


**Scheme 1**



15 wherein A, B,  $R_1$ ,  $R_2$ ,  $R_3$ ,  $R_4$ ,  $R_5$  and  $R_6$  are the same as defined as above.

Specifically, the compound of formula (I-1) may be prepared by a process which comprises: reacting a compound of formula (IV) with a compound of formula (V-1) or (V-2) to give a compound of formula (VI-1); and reacting the compound of formula (VI-1) with a compound of formula (VII).

Scheme 2



- 10 -

wherein A, B, R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub> and R<sub>6</sub> are the same as defined as above.

Further, the compound of formula(I-2) may be prepared by a process which comprises: hydrolyzing a compound of formula(IV) at its 4-position to give a compound of formula(VIII); reacting the compound of formula(VIII) with a compound of formula (V-1) or (V-2) to give a compound of formula(IX); chlorinating the compound of formula(IX) at its 4-position to give a compound of formula (VI-2); and then reacting the compound of formula (VI-2) with a compound of formula (VII).

In the processes of Scheme 1 and Scheme 2, the compound of formula(IV) may be prepared by using a known process [see, e.g., *J. Heterocyclic Chem.*, 28, 231(1991); and *Org. Synth.*, Coll. Vol, 638], and the compounds of formula (V-1) and (V-2) may be prepared in accordance with the process disclosed in European Patent No. 230871. The compound of formula(VII) is commercially available(for example from Aldrich Co. in U.S.A.)

As shown in Scheme 1 and Scheme 2, the pyrimidine compounds (IV) and (VIII) are reacted with the compounds of formula (V-1) or (V-2) in the presence of an appropriate solvent and a base for 1 to 24 hours to give the compounds of formula (VI-1) or (VI-2), respectively. Suitable solvents for this reaction may include dichloromethane, acetone, acetonitrile and dimethylformamide. The reaction temperature preferably ranges from a room temperature to 150°C. Suitable bases for this reaction may include triethylamine, N,N-dimethylaniline and pyridine.

The substituted pyrimidine compounds of formula(VI-1) and (VI-2) so obtained are then reacted with the compounds of formula(VII) in an appropriate solvent for 2 to 5 hours to give the present compounds of formula (I-1) and (I-2), respectively. Suitable solvents for this reaction may include dimethylformamide, p-dioxane, dimethylsulfoxide and the like. The reaction temperature preferably ranges from

- 11 -

80°C and 140°C.

In the process of Scheme 2, prior to the reaction with the compound of formula (V-1) or (V-2), the 4-position of the compound of formula (IV) may be hydrolyzed selectively 5 using NaOH solution in an appropriate solvent. Suitable solvents for this reaction may include acetone, acetonitrile and tetrahydrofuran.

The compound of formula (VI-2) is prepared from the compound of formula (IX) by using a chlorinating agent such 10 as phosphorous oxychloride.

The compounds of formula (VI-1) and (VI-2) prepared as above are novel and useful as intermediates for the preparation of the pyrimidine compounds of formula (I-1) or (I-2). Therefore, the present invention encompasses, within 15 its scope, the novel compounds of formula (VI-1) or (VI-2) and processes for the preparation thereof.

The compounds of the present invention may be administered, either orally or intraperitoneally, in an effective amount ranging from 0.1 to 500 mg/kg, preferably 20 from 1.0 to 100 mg/kg into a subject patient per day.

The present invention further includes, within its scope, pharmaceutically acceptable salts of the compounds of formula (I-1) and (I-2). The non-toxic salts which fall within the scope of the present invention may include 25 inorganic acid salts such as hydrochloride, sulfate, phosphate and nitrate, and organic acid salts such as tartrate, fumarate, citrate, mesylate and acetate.

The pharmaceutically acceptable salts may be prepared in accordance with a known method, e.g., by reacting the 30 compounds of formula (I-1) or (I-2) with the acids mentioned above in the presence of a solvent, e.g., ethyl alcohol, dichloromethane, ethyl acetate and diethyl ether.

The present invention also includes within its scope pharmaceutical compositions comprising one or more of the 35 inventive compounds as an active ingredient, in association with a pharmaceutically acceptable carrier, excipient and/or other additives, if necessary. The active ingredient

- 12 -

present in the composition may range from 0.1% to 99.9% by weight thereof.

The following Examples are given for the purpose of illustration only, and are not intended to limit the scope 5 of the invention. 1-Methyl-1,2,3,4-tetrahydroisoquinoline, (R)-1-methyl-1,2,3,4-tetrahydroisoquinoline and (S)-1-methyl-1,2,3,4-tetrahydroisoquinoline were prepared by the same method as described in Preparation of WO 94/14795.

10

Preparation 1: Preparation of 7-methyl-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine

Step 1: 2-(3-thienyl)chloroethane

15

Thionyl chloride(17ml, 0.23mol) was added dropwise to a mixture solution of 2-(3-thienyl)ethanol(22.4ml, 0.2mol) and chloroform(60ml) while maintaining the temperature of the reaction system below 10°C, followed by stirring at room 20 temperature for 1 hour. Then the reaction mixture was concentrated under a reduced pressure and distilled in vacuo to give 24g of the titled compound. (Yield : 81.5 %)

Step 2: 7-methyl-6,7-dihydrothieno[2,3-c]pyridine

25

To a solution of 2-(3-thienyl)chloroethane(20g, 0.136mol) prepared in the above Step 1 and anhydrous acetonitrile(350ml) was added tin(IV) chloride(20ml, 0.17mol) at room temperature. The reaction mixture was 30 heated to reflux for 16 hours and cooled, to which water was added to remove excess tin(IV) chloride. And then the reaction mixture was washed by dichloromethane. The water layer was separated and basified with aqueous  $K_2CO_3$  solution under ice-cooling and then extracted with dichloromethane. 35 The combined dichloromethane layers were dried over magnesium sulfate and concentrated to give 10.56g of the titled compound. (Yield : 51%)

- 13 -

**Step 3: 7-methyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridine**

Sodium borohydride(4.4g, 116mmol) was added portionwise at room temperature to a mixture solution of 5 7-methyl-6,7-dihydrothieno[2,3-c]pyridine(10.5g, 69.4mmol) prepared in the above Step 2 and ethanol(100ml). After stirring for 1 hour, the reaction mixture was diluted with water, and extracted with dichloromethane. The combined dichloromethane layers were dried over magnesium sulfate and 10 concentrated to give 10.34g of the titled compound.  
(Yield: 97%)

**Preparation 2: Preparation of 2,4-dichloro-6-ethylpyrimidine**

**15 Step 1: 2-mercaptop-6-ethylpyrimidine-4-one**

To a solution of sodium methoxide(24g, 0.44mol) and ethanol(180ml) were added thiourea(15.22g, 0.2mol) and methyl propionylacetate(25.1ml, 0.2mol). After distillating 20 solvent slowly, water(200ml) was added to the reaction mixture, which was then heated to reflux for 30 minutes. Active carbon was added to the reaction mixture, which was then stirred for 5 minutes and filtered. The filtrate was cooled to a room temperature and acidified by glacial acetic acid and the resulting solid was filtered and dried to give 25 29g of the titled compound. (Yield : 93%)

**Step 2: 2,4-dihydroxy-6-ethylpyrimidine**

30 A mixture solution of chloroacetic acid(33.3g, 0.352mol), water(400ml) and 2-mercaptop-6-ethylpyrimidine-4-one(29g, 0.186mol) prepared in the above Step 1 was heated to reflux for 14 hours and cooled to a room temperature. To the reaction mixture was added conc. HCl(95ml) and the 35 mixture was heated to reflux for 1 day. After the reaction mixture was cooled to a room temperature and concentrated under a reduced pressure, the residue was diluted with

- 14 -

water. After stirring for 2 hours, the resulting solid was filtered and dried to give 11.16g of the titled compound. (Yield : 43%)

5 Step 3: 2,4-dichloro-6-ethylpyrimidine

A mixture of phosphorous oxychloride(43ml), N,N-dimethyl aniline(6.6ml) and 2,4-dihydroxy-6-ethyl pyrimidine(11.12g, 79.3mmol) prepared in the above Step 2 10 was heated to reflux for 6 hours. The reaction mixture was cooled to a room temperature and diluted with dichloro- methane. The diluted solution was added slowly to ice water, while maintaining the temperature of the reaction system below 10°C and the mixture was extracted with 15 dichloromethane. The combined dichloromethane layers were dried over magnesium sulfate and concentrated to give 13.10g of the titled compound as an oily form. (Yield : 93.3%)

Preparation 3: Preparation of 2,4-dichloro-6-propyl- 20 pyrimidine

In accordance with the same procedure as in Preparation 2, except that sodium methoxide(24g, 0.44mol), thiourea (15.22g, 0.2mol), ethyl butyrylacetate(31.6ml, 0.2mol) and 25 ethanol(180ml) were used as starting materials, 10.5g of the titled compound was prepared as an oily form.

Preparation 4: Preparation of 2,4-dichloro-5-methyl-6-ethyl- 30 pyrimidine

In accordance with the same procedure as in Preparation 2, except that sodium methoxide(24g, 0.44mol), thiourea (15.22g, 0.2mol), ethyl 2-propionyl propionate(31.6g, 0.2mol) and ethanol(180ml) were used as starting materials, 35 16.5g of the title compound was prepared as an oily form.

Example 1: Synthesis of 2-(2-methyl-4-fluorophenylamino)-4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride

5 Step 1: 4-(1-Methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)-2-chloropyrimidine

A mixture solution of 2,4-dichloropyrimidine(3.0g, 20mmol), 1-methyl-1,2,3,4-tetrahydroisoquinoline(3.3g, 10 22mmol), triethylamine(3.4ml, 24.4mmol) and N,N-dimethyl formamide(20ml) was stirred for 5 hours, diluted with dichloromethane, washed with water several times. The dichloromethane layer was separated, dried over anhydrous sodium sulfate and then concentrated under a reduced 15 pressure. The resulting residue was crystallized by silica gel column chromatography to give 1.5g of the titled compound. (Yield: 28.9%)

Step 2: 2-(2-Methyl-4-fluorophenylamino)-4-(1-methyl-1,2,20 3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride

2-Methyl-4-fluoroaniline(1.1ml, 10.2mmol) was added to a mixture solution of 4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)-2-chloropyrimidine(1.5g, 5.8mmol) and 25 dimethylformamide(10ml). The reaction mixture was stirred for 3 hours at 110-120°C, cooled to a room temperature, diluted with dichloromethane, and then washed with water. The dichloromethane layer was separated, basified with aqueous sodium hydroxide, washed with water, dried and 30 concentrated. The resulting residue was crystallized by silica gel column chromatography to give free base form of the titled compound. To a mixture solution of the free base form of the titled compound and ethyl ether was added aqueous hydrochloric acid and the resulting titled compound 35 was filtered and dried in vacuo. Recrystallization from ethanol afforded 1.2g of the titled compound as a white crystalline solid.

- 16 -

Yield: 58.6%

M.P.: 160-163°C

<sup>1</sup>H-NMR(DMSO-d<sub>6</sub>): δ 1.49(d, 3H), 2.30(s, 3H), 2.90(m, 2H),  
3.45(m, 1H), 4.20(bs, 1H), 5.40(bs, 1H), 6.05(d, 1H),  
5 6.45(s, 1H), 6.90(m, 2H), 7.18(m, 4H), 7.88(m, 4H), 7.95(d,  
1H).

Example 2: Synthesis of 6-methyl-2-(2-methyl-4-fluorophenylamino)-4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)-10 pyrimidine hydrochloride

Step 1: 6-methyl-4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)-2-chloropyrimidine

15 In accordance with the same procedure as in Step 1 of Example 1, except that 6-methyl-2,4-dichloropyrimidine (6.52g, 40mmol), 1-methyl-1,2,3,4-tetrahydroisoquinoline (6.6g, 44mmol), triethylamine(6.8ml, 48.8mmol) and N,N-dimethylformamide(30ml) were used as starting materials,  
20 5.5g of the titled compound was prepared. (Yield: 50.2%)

Step 2: 6-methyl-2-(2-methyl-4-fluorophenylamino)-4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride

25 After 2-methyl-4-fluoroaniline(1.1ml, 10.2mmol) was added to a mixture solution of 6-methyl-4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)-2-chloropyrimidine(1.5g, 5.5mmol) and dimethylformamide(10ml), 1.2g of the titled compound was obtained in accordance with the same procedure as in Step 2 of Example 1.

Yield: 51.7%

M.P.: 177-179°C

<sup>1</sup>H-NMR(DMSO-d<sub>6</sub>): δ 1.42(d, 3H), 2.30(s, 3H), 2.32(s, 3H),  
35 2.90(m, 2H), 3.50(qq, 1H), 4.22(qq, 1H), 5.42(qq, 1H),  
6.70(s, 1H), 7.18(m, 6H), 7.63(m, 1H), 9.80(s, 1H),  
13.30(bs, 1H).

- 17 -

Example 3: Synthesis of 6-methyl-4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)-2-(4-fluorophenylamino)pyrimidine hydrochloride

5 After 4-fluoroaniline(0.8ml, 8.4mmol) was added to a mixture solution of 6-methyl-4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)-2-chloropyrimidine(1.5g, 5.5mmol) and dimethylformamide (10ml), 1.5g of the title compound was obtained in accordance with the same procedure as in Step 2  
10 of Example 1.

Yield: 70.7%

M.P.: 194-196°C

<sup>1</sup>H-NMR(DMSO-d<sub>6</sub>): δ 1.50(d, 3H), 2.38(s, 3H), 2.92(bs, 2H),  
3.50(m, 1H), 4.30(qq, 1H), 5.58(qq, 1H), 6.70(s, 1H),  
15 7.1-7.40(m, 6H), 7.60(m, 2H), 10.50(s, 1H), 13.10(bs, 1H).

Example 4: Synthesis of 6-methyl-2-(N-methylphenylamino)-4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride

20 After N-methylaniline(0.9ml, 8.4mmol) was added to a mixture solution of 6-methyl-4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)-2-chloropyrimidine(1.5g, 5.5mmol) and dimethylformamide(10ml), 1.2g of the titled compound was obtained in accordance with the same procedure as in Step 2  
25 of Example 1

Yield: 57.3%

M.P.: 170-172°C

<sup>1</sup>H-NMR(DMSO-d<sub>6</sub>): δ 1.40(d, 3H), 2.38(s, 3H), 2.95(m, 2H),  
30 3.58(s, 3H), 3.60(bs, 1H), 4.30(qq, 1H), 5.50(qq, 1H),  
6.70(s, 1H), 7.10-7.38(m, 4H), 7.40-7.60(m, 5H), 12.00(s, 1H).

Example 5: Synthesis of 6-ethyl-2-(2-methyl-4-fluorophenylamino)-4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride

- 18 -

**Step 1: 6-ethyl-4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)-2-chloropyrimidine**

In accordance with the same procedure as in Step 1 of Example 1, except that 1-methyl-1,2,3,4-tetrahydroisoquinoline(4.1g, 27.8mmol), triethylamine(4.7ml, 33.7mmol), N,N-dimethylformamide(20ml) and 6-ethyl-2,4-dichloropyrimidine(4.9g, 27.7mmol) obtained in Preparation 2 were used as starting materials, 5.58g of the titled compound was prepared. (Yield: 70%)

**Step 2: 6-ethyl-2-(2-methyl-4-fluorophenylamino)-4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride**

After 2-methyl-4-fluoroaniline(0.77ml, 6.93mmol) was added to a mixture solution of 6-ethyl-4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)-2-chloropyrimidine(1.0g, 3.47mmol) and dimethylformamide(5ml), 0.92g of the titled compound was obtained in accordance with the same procedure as in Step 2 of Example 1.

Yield: 64%

M.P.: 172-174°C

$^1\text{H-NMR}(\text{CDCl}_3)$ :  $\delta$  1.38-1.60(tt+dd, 6H), 2.43(ss, 3H), 2.68-3.06(m, 4H), 3.76(m, 1H), 3.94(m, 1H), 5.33(qq, 1H), 6.01(ss, 1H), 6.85-7.30(m, 6H), 7.58(t, 1H), 9.83(s, 1H), 14.00(s, 1H).

**Example 6: Synthesis of 6-ethyl-2-(4-fluorophenylamino)-4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride**

After 4-fluoroaniline(0.38ml, 4.01mmol) was added to a mixture solution of 6-ethyl-4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)-2-chloropyrimidine (0.57g, 1.98mmol) and dimethylformamide (5ml), 0.17g of the titled compound was obtained in accordance with the same procedure as in Step 2

- 19 -

of Example 1

Yield: 22%

M.P.: 156-158°C

$^1\text{H-NMR(DMSO-d}_6\text{)}$ :  $\delta$  1.29(t, 3H), 1.49(d, 3H), 2.65(q, 2H),

5 2.93-2.96(m, 2H), 3.70(m, 1H), 4.05-4.60(m, 1H), 5.60(qq, 1H), 7.10-7.55(m, 6H), 7.60-7.65(m, 2H), 10.60(s, 1H), 10.90(s, 1H).

Example 7: Synthesis of 6-ethyl-2-(N-methylphenylamino)-4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride

After N-methylaniline(0.46ml, 4.25mmol) was added to a mixture solution of 6-ethyl-4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)-2-chloropyrimidine(0.61g, 2.12mmol) and dimethylformamide(5ml), 0.50g of the titled compound was obtained in accordance with the same procedure as in Step 2 of Example 1.

Yield: 60%

20 M.P.: 109-111°C

$^1\text{H-NMR(DMSO-d}_6\text{)}$ :  $\delta$  1.22(t, 3H), 1.43(dd, 3H), 2.78(q, 2H), 2.95(s, 1H), 3.30(m, 1H), 3.62(s, 3H), 4.37(mm, 1H), 5.70(q, 1H), 6.70(s, 1H), 7.06-7.58(m, 9H), 12.15(s, 1H).

Example 8: Synthesis of 6-ethyl-2-(2-methylphenylamino)-4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride

After 2-methylaniline(0.46ml, 4.31mmol) was added to a mixture solution of 6-ethyl-4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)-2-chloropyrimidine(0.61g, 2.12mmol) and dimethylformamide(5ml), 0.52g of the titled compound was obtained in accordance with the same procedure as in Step 2 of Example 1.

35 Yield: 62%

M.P.: 78-81°C

$^1\text{H-NMR(DMSO-d}_6\text{)}$ :  $\delta$  1.80-2.20(m, 6H), 2.90(s, 3H), 3.07(s,

- 20 -

1H), 3.24(q, 2H), 3.43(s, 1H), 3.96(s, 3H), 4.16(mm, 1H), 4.88(mm, 1H), 6.08(qq, 1H), 7.23(ss, 1H), 7.64-7.90(m, 7H), 8.32(t, 1H), 10.50(s, 1H), 14.10(s, 1H).

5 Example 9: Synthesis of 2-(2-methyl-4-fluorophenylamino)-4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)-6-propyl-pyrimidine hydrochloride

Step 1: 4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)-10 6-propyl-2-chloropyrimidine

In accordance with the same procedure as in Step 1 of Example 1, except that 1-methyl-1,2,3,4-tetrahydroisoquinoline(1.6g, 10.9mmol), triethylamine(1.6ml, 11.5mmol), 15 N,N-dimethylformamide(20ml) and 2,4-dichloro-6-propyl pyrimidine(1.8g, 9.4mmol) obtained in Preparation 3 were used as starting materials, 1.6g of the titled compound was prepared. (Yield: 56.4%)

20 Step 2: 2-(2-methyl-4-fluorophenylamino)-4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)-6-propylpyrimidine hydrochloride

After 4-fluoro-2-methylaniline(0.35ml, 3.15mmol) was 25 added to a mixture solution of 4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)-6-propyl-2-chloropyrimidine(0.5g, 1.66mmol) and dimethylformamide(5ml), 0.2g of the titled compound was obtained in accordance with the same procedure as in Step 2 of Example 1.

30 Yield: 28.2%

M.P.: 95-97°C

<sup>1</sup>H-NMR(DMSO-d<sub>6</sub>): δ 1.00(t, 3H), 1.50(dd, 3H), 1.81(q, 2H), 2.35(s, 3H), 2.70(t, 2H), 2.94(bd, 2H), 3.60(mm, 1H), 4.30(dd, 1H), 5.55(dd, 1H), 6.70(s, 1H), 7.22(bs, 6H), 35 7.75(bs, 1H), 9.90(s, 1H), 13.30(bs, 1H).

- 21 -

Example 10: Synthesis of 4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)-6-propyl-2-(4-fluorophenylamino)pyrimidine hydrochloride

5 After 4-fluoroaniline(0.27ml, 2.85mmol) was added to a mixture solution of 4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)-6-propyl-2-chloropyrimidine(0.5g, 1.66mmol) and dimethylformamide(5ml), 0.3g of the titled compound was obtained in accordance with the same procedure as in Step 2  
10 of Example 1.

Yield: 43.8%

M.P.: 100-105°C

<sup>1</sup>H-NMR(DMSO-d<sub>6</sub>): δ 0.96(t, 3H), 1.54(m, 3H), 1.75(q, 2H),  
15 2.60(t, 2H), 2.96(m, 2H), 3.62(mm, 1H), 4.35(qq, 1H),  
5.60(qq, 1H), 6.70(d, 1H), 7.00-7.40(m, 6H), 7.62(m, 2H).

Example 11: 2-(N-methylphenylamino)-4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)-6-propylpyrimidine hydrochloride

20 After N-methylaniline(0.27ml, 2.49mmol) was added to a mixture solution of 4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)-6-propyl-2-chloropyrimidine(0.5g, 1.66mmol) and dimethylformamide (5ml), 0.5g of the title compound was obtained in accordance with the same procedure as in Step 2  
25 of Example 1.

Yield: 73.6%

M.P.: 92-94°C

<sup>1</sup>H-NMR(DMSO-d<sub>6</sub>): δ 0.96(t, 3H), 1.46(dd, 3H), 1.59(q, 2H),  
2.57(t, 2H), 2.90(bd, 2H), 3.50(mm+d, 4H), 4.35(qq, 1H),  
30 5.56(qq, 1H), 6.65(d, 1H), 7.00-7.70(m, 9H).

Example 12: Synthesis of 5,6-dimethyl-2-(2-methyl-4-fluorophenylamino)-4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride

35

Step 1: 5,6-Dimethyl-2,4-dichloropyrimidine

- 22 -

A mixture solution of 5,6-dimethyl-2,4-dihydroxy pyrimidine(72g, 0.51mol), phosphorus oxychloride(250ml) and N,N-dimethylaniline(41ml) was heated to reflux for 3 hours. After cooling to room temperature, the reaction mixture was 5 added slowly to ice water. The resulting solid was filtered and recrystallized from dichloromethane to give 54.3g of the titled compound. (Yield: 60%)

Step 2: 5,6-Dimethyl-4-(1-methyl-1,2,3,4-tetrahydroiso 10 quinolin-2-yl)-2-chloropyrimidine

In accordance with the same procedure as in Step 1 of Example 1, except that 1-methyl-1,2,3,4-tetrahydroiso quinoline(3.9g, 26.4mmol) and 5,6-dimethyl-2,4-dichloro 15 pyrimidine(4.3g, 24mmol) prepared in the above Step 1 were used as starting materials, 4.17g of the titled compound was prepared. (Yield: 60.4%)

Step 3: 5,6-Dimethyl-2-(2-methyl-4-fluorophenylamino)- 20 4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride

After 2-methyl-4-fluoroaniline(1.1ml, 9.9mmol) was added to a mixture solution of 5,6-dimethyl-4-(1-methyl- 25 1,2,3,4-tetrahydroisoquinolin-2-yl)-2-chloropyrimidine(1.4g, 4.8mmol) prepared in the above Step 2 and dimethylformamide (10ml), 1.35g of the titled compound was obtained in accordance with the same procedure as in Step 2 of Example 1.

30 Yield: 68%

M.P.: 201-205°C

<sup>1</sup>H-NMR(DMSO-d<sub>6</sub>): δ 1.58(d, 3H), 2.17(s, 3H), 2.36(s, 3H), 2.89(bd, 1H), 3.08(m, 1H), 3.59(m, 1H), 4.19(bd, 1H), 5.38(q, 1H), 7.34(m, 6H), 7.60(m, 2H), 10.40(s, 1H).

35

Example 13: Synthesis of (R)-5,6-Dimethyl-2-(2-methyl-4-fluorophenylamino)-4-(1-methyl-1,2,3,4-tetrahydroiso-

- 23 -

quinolin-2-yl)pyrimidine hydrochloride

Step 1: (R)-5,6-Dimethyl-4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)-2-chloropyrimidine

5

In accordance with the same procedure as in Step 1 of Example 1, except that (R)-1-methyl-1,2,3,4-tetrahydroisoquinoline(3.9g, 26.4mmol) and 5,6-dimethyl-2,4-dichloropyridine(4.3g, 24mmol) were used as starting materials, 10 4.35g of the titled compound was prepared. (Yield: 63%)

Step 2: (R)-5,6-Dimethyl-2-(2-methyl-4-fluorophenylamino)-4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride

15

After 2-methyl-4-fluoroaniline(1.1ml, 9.9mmol) was added to a mixture solution of (R)-5,6-dimethyl-4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)-2-chloropyrimidine(1.4g, 4.8mmol) obtained in the above Step 1 and 20 dimethylformamide(10ml), 1.10g of the titled compound was obtained in accordance with the same procedure as in Step 2 of Example 1.

Yield: 55.5%

M.P.: 203-205°C

25  $^1\text{H-NMR(DMSO-d}_6\text{)}: \delta$  1.58(d, 3H), 2.17(s, 3H), 2.36(s, 3H), 2.89(bd, 1H), 3.08(m, 1H), 3.59(m, 1H), 4.19(bd, 1H), 5.38(q, 1H), 7.34(m, 6H), 7.60(m, 2H), 10.40(s, 1H).

Example 14: Synthesis of (S)-5,6-dimethyl-2-(2-methyl-

30 4-fluorophenylamino)-4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride

Step 1: (S)-5,6-Dimethyl-4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)-2-chloropyrimidine

35

In accordance with the same procedure as in Step 1 of Example 1, except that (S)-1-methyl-1,2,3,4-tetrahydroiso-

- 24 -

quinoline(3.9g, 26.4mmol) and 5,6-dimethyl-2,4-dichloropyridine(4.3g, 24mmol) were used as starting materials, 4.2g of the titled compound was prepared. (Yield: 60.8%)

5 Step 2: (S)-5,6-Dimethyl-2-(2-methyl-4-fluorophenylamino)-4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride

After 2-methyl-4-fluoroaniline(1.1ml, 9.9mmol) was  
10 added to a mixture solution of (S)-5,6-dimethyl-4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)-2-chloropyrimidine(1.4g, 4.8mmol) obtained in the above Step 1 and dimethylformamide (10ml), 0.90g of the title compound was obtained in accordance with the same procedure as in Step 2 of  
15 Example 1.

Yield: 45.5%

M.P.: 202-204°C

<sup>1</sup>H-NMR(DMSO-d<sub>6</sub>): δ 1.58(d, 3H), 2.17(s, 3H), 2.36(s, 3H),  
2.89(bd, 1H), 3.08(m, 1H), 3.59(m, 1H), 4.19(bd, 1H),  
20 5.38(q, 1H), 7.34(m, 6H), 7.60(m, 2H), 10.40(s, 1H).

Example 15: Synthesis of 5,6-dimethyl-2-(4-fluorophenylamino)-4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride

25 After 4-fluoroaniline(1.0ml, 10mmol) was added to a mixture solution of 5,6-dimethyl-4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)-2-chloropyrimidine(1.4g, 4.8mmol) and dimethylformamide(10ml), 1.32g of the title compound was obtained in accordance with the same procedure as in Step 2 of Example 1.

Yield: 69%

M.P.: 205-208°C

<sup>1</sup>H-NMR(DMSO-d<sub>6</sub>): δ 1.58(d, 3H), 2.17(s, 3H), 2.36(s, 3H),  
35 2.89(bd, 1H), 3.08(m, 1H), 3.59(m, 1H), 4.19(bd, 1H),  
5.38(q, 1H), 7.34(m, 6H), 7.60(m, 2H), 10.40(s, 1H).

- 25 -

Example 16: Synthesis of (R)-5,6-dimethyl-2-(4-fluorophenyl-amino)-4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)-pyrimidine hydrochloride

5 After 4-fluoroaniline(1ml, 10mmol) was added to a mixture solution of (R)-5,6-dimethyl-4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)-2-chloropyrimidine(1.4g, 4.8mmol) and dimethylformamide(10ml), 1.20g of the titled compound was obtained in accordance with the same procedure  
10 as in Step 2 of Example 1.

Yield: 62.7%

M.P.: 205-207°C

<sup>1</sup>H-NMR(DMSO-d<sub>6</sub>): δ 1.58(d, 3H), 2.17(s, 3H), 2.36(s, 3H),  
15 2.89(bd, 1H), 3.08(m, 1H), 3.59(m, 1H), 4.19(bd, 1H),  
5.38(q, 1H), 7.34(m, 6H), 7.60(m, 2H), 10.40(s, 1H).

Example 17: Synthesis of (S)-5,6-dimethyl-2-(4-fluorophenyl-amino)-4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)-pyrimidine hydrochloride

20 After 4-fluoroaniline(1ml, 10mmol) was added to a mixture solution of (S)-5,6-dimethyl-4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)-2-chloropyrimidine(1.4g, 4.8mmol) and dimethylformamide(10ml), 1.50g of the titled compound was obtained in accordance with the same procedure  
25 as in Step 2 of Example 1.

Yield: 78.3%

M.P.: 204-206°C

<sup>1</sup>H-NMR(DMSO-d<sub>6</sub>): δ 1.58(d, 3H), 2.17(s, 3H), 2.36(s, 3H),  
30 2.89(bd, 1H), 3.08(m, 1H), 3.59(m, 1H), 4.19(bd, 1H),  
5.38(q, 1H), 7.34(m, 6H), 7.60(m, 2H), 10.40(s, 1H).

Example 18: Synthesis of 5,6-dimethyl-2-(N-methylphenyl-amino)-4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)-pyrimidine hydrochloride

After N-methylaniline(1.5ml, 14mmol) was added to a

- 26 -

5 mixture solution of 5,6-dimethyl-4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)-2-chloropyrimidine(1.9g, 6.6mmol) and dimethylformamide(10ml), 0.25g of the titled compound was obtained in accordance with the same procedure as in Step 2 of Example 1.

Yield: 9%

M.P.: 220-222°C

10  $^1\text{H-NMR}(\text{CDCl}_3)$ :  $\delta$  1.34(d, 3H), 2.19(s, 3H), 2.77(s, 3H), 2.93(bd, 2H), 3.48(m, 1H), 3.98(s, 3H), 4.04(bd, 1H), 5.02(m, 1H), 6.88(m, 1H), 7.16-7.42(m, 5H), 7.58(m, 3H), 13.42(bd, 1H).

15 Example 19: Synthesis of (R)-5,6-Dimethyl-2-(N-methylphenyl-amino)-4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)-pyrimidine hydrochloride

After N-methylaniline(1.04ml, 9.6mmol) was added to a mixture solution of (R)-5,6-dimethyl-4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)-2-chloropyrimidine(1.4g, 4.8mmol) and dimethyl formamide(10ml), 0.55g of the title compound was obtained in accordance with the same procedure as in Step 2 of Example 1.

Yield: 29%

M.P.: 221-223°C

25  $^1\text{H-NMR}(\text{CDCl}_3)$ :  $\delta$  1.34(d, 3H), 2.19(s, 3H), 2.77(s, 3H), 2.93(bd, 2H), 3.48(m, 1H), 3.98(s, 3H), 4.04(bd, 1H), 5.02(m, 1H), 6.88(m, 1H), 7.16-7.42(m, 5H), 7.58(m, 3H), 13.42(bd, 1H).

30 Example 20: Synthesis of (S)-5,6-dimethyl-2-(N-methylphenyl-amino)-4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)-pyrimidine hydrochloride

35 After N-methylaniline(1.04ml, 9.6mmol) was added to a mixture solution of (S)-5,6-dimethyl-4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)-2-chloropyrimidine(1.4g, 4.8mmol) and dimethylformamide(10ml), 0.70g of the titled

- 27 -

compound was obtained in accordance with the same procedure as in Step 2 of Example 1.

Yield: 37%

M.P.: 220-223°C

5  $^1\text{H-NMR}(\text{CDCl}_3)$ :  $\delta$  1.34(d, 3H), 2.19(s, 3H), 2.77(s, 3H), 2.93(bd, 2H), 3.48(m, 1H), 3.98(s, 3H), 4.04(bd, 1H), 5.02(m, 1H), 6.88(m, 1H), 7.16-7.42(m, 5H), 7.58(m, 3H), 13.42(bd, 1H).

10 Example 21: Synthesis of 5,6-dimethyl-2-(phenylamino)-4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride

15 After aniline(0.53ml, 5.5mmol) was added to a mixture solution of 5,6-dimethyl-4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)-2-chloropyrimidine(0.72g, 2.5mmol) and dimethylformamide(5ml), 0.21g of the titled compound was obtained in accordance with the same procedure as in Step 2 of Example 1.

20 Yield: 22%

M.P.: 243-245°C

25  $^1\text{H-NMR}(\text{DMSO-d}_6)$ :  $\delta$  1.58(d, 3H), 2.15(s, 3H), 2.34(s, 3H), 2.90(bd, 1H), 3.12(m, 1H), 3.64(m, 1H), 4.25(m, 1H), 5.42(q, 1H), 7.21(m, 5H), 7.43(m, 2H), 7.56(m, 2H), 10.30(s, 1H), 13.35(bd, 1H).

Example 22: Synthesis of (R)-5,6-Dimethyl-2-(4-phenylamino)-4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)-pyrimidine hydrochloride

30

After aniline(0.53ml, 5.5mmol) was added to a mixture solution of (R)-5,6-dimethyl-4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)-2-chloropyrimidine(0.72g, 2.5mmol) and dimethylformamide(5ml), 0.25g of the titled compound was obtained in accordance with the same procedure as in Step 2 of Example 1.

Yield: 26%

- 28 -

M.P.: 243-246°C

<sup>1</sup>H-NMR(DMSO-d<sub>6</sub>): δ 1.58(d, 3H), 2.15(s, 3H), 2.35(s, 3H), 2.89(bd, 1H), 3.12(m, 1H), 3.64(m, 1H), 4.25(m, 1H), 5.42(q, 1H), 7.20(m, 5H), 7.43(m, 2H), 7.56(m, 2H), 10.30(s, 1H), 13.35(bd, 1H).

Example 23: Synthesis of (S)-5,6-Dimethyl-2-(4-fluorophenyl-amino)-4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)-pyrimidine hydrochloride

10

After aniline(0.53ml, 5.5mmol) was added to a mixture solution of (S)-5,6-dimethyl-4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)-2-chloropyrimidine(0.72g, 2.5mmol) and dimethylformamide(5ml), 0.20g of the titled compound was obtained in accordance with the same procedure as in Step 2 of Example 1.

Yield: 21%

M.P.: 243-245°C

<sup>1</sup>H-NMR(DMSO-d<sub>6</sub>): δ 1.58(d, 3H), 2.15(s, 3H), 2.34(s, 3H), 2.89(bd, 1H), 3.12(m, 1H), 3.64(m, 1H), 4.25(m, 1H), 5.42(q, 1H), 7.20(m, 5H), 7.43(m, 2H), 7.56(m, 2H), 10.30(s, 1H), 13.35(bd, 1H).

Example 24: Synthesis of 5,6-Dimethyl-2-(2-methylphenyl-amino)-4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)-pyrimidine hydrochloride

After 2-methylaniline(1.0ml, 9.6mmol) was added to a mixture solution of 5,6-Dimethyl-4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)-2-chloropyrimidine(1.34g, 4.6mmol) and dimethylformamide(5ml), 0.65g of the titled compound was obtained in accordance with the same procedure as in Step 2 of Example 1.

Yield: 36%

35 M.P.: 94-96°C

<sup>1</sup>H-NMR(DMSO-d<sub>6</sub>): δ 1.52(d, 3H), 2.17(s, 3H), 2.30(s, 3H), 2.37(s, 3H), 2.82(d, 1H), 3.01(m, 1H), 3.54(t, 1H), 4.15(bd,

- 29 -

1H), 5.31(t, 1H), 7.15(m, 5H), 7.30(m, 2H), 7.73(d, 1H), 9.55(s, 1H), 13.73(bd, 1H).

Example 25: Synthesis of 5,6-dimethyl-2-(4-methylphenyl-5 amino)-4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)-pyrimidine hydrochloride

After p-toluidine(0.45g, 4.20mmol) was added to a mixture solution of 5,6-dimethyl-4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)-2-chloropyrimidine(0.80g, 2.78mmol) and dimethylformamide(5ml), 0.30g of the titled compound was obtained in accordance with the same procedure as in Step 2 of Example 1.

Yield: 27%

15 M.P.: 243-245°C

<sup>1</sup>H-NMR(CDCl<sub>3</sub>): δ 1.64(d, 3H), 2.18(s, 3H), 2.36(s, 3H), 2.44(s, 3H), 2.87(bd, 1H), 3.28(tt, 1H), 3.60(tt, 1H), 4.30(bd, 1H), 5.42(q, 1H), 7.08-7.23(m, 6H), 7.52(d, 2H), 10.20(s, 1H), 14.10(bs, 1H).

20

Example 26: Synthesis of 5-methyl-6-ethyl-2-(2-methyl-4-fluorophenylamino)-4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride

25 Step 1: 5-Methyl-6-ethyl-4-(1,2,3,4-tetrahydroisoquinolin-2-yl)-2-chloropyrimidine

In accordance with the same procedure as in Step 1 of Example 1, except that 1-methyl-1,2,3,4-tetrahydroisoquinoline (2.3g, 15.6mmol) and 2,4-dichloro-5-methyl-6-ethylpyrimidine (2.7g, 14.1mmol) prepared in Preparation 4 were used as starting materials, 2.3g of the titled compound was prepared. (Yield: 54%)

35 Step 2: 5-Methyl-6-ethyl-2-(2-methyl-4-fluorophenylamino)-4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride

- 30 -

After 4-fluoro-2-methylaniline(0.55ml, 4.95mmol) was added to a mixture solution of 5-methyl-6-ethyl-4-(1,2,3,4-tetrahydroisoquinolin-2-yl)-2-chloropyrimidine(0.80g, 2.65mmol) and dimethylformamide (5ml), 0.25g of the titled compound was obtained in accordance with the same procedure as in Step 2 of Example 1.

5 Yield: 22.1%

M.P.: 171-173°C

10  $^1\text{H-NMR(DMSO-d}_6\text{): } \delta 1.20(\text{t, 3H}), 1.46(\text{d, 3H}), 2.16(\text{s, 3H}), 2.22(\text{s, 3H}), 2.68(\text{q, 2H}), 2.95(\text{m, 1H}), 3.48(\text{t, 1H}), 4.12(\text{d, 2H}), 5.20(\text{q, 1H}), 6.90\text{-7.30(m, 6H), 7.58(m, 1H).}$

15 Example 27: Synthesis of 5-methyl-6-ethyl-2-(4-fluorophenyl-amino)-4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride

After 4-fluoroaniline(0.50ml, 5.28mmol) was added to a mixture solution of 5-methyl-6-ethyl-4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)-2-chloropyrimidine (0.80g, 2.65mmol) and dimethylformamide(5ml), 0.55g of the titled compound was obtained in accordance with the same procedure as in Step 2 of Example 1.

20 Yield: 50.3%

M.P.: 198-200°C

25  $^1\text{H-NMR(DMSO-d}_6\text{): } \delta 1.20(\text{t, 3H}), 1.56(\text{d, 3H}), 2.18(\text{s, 3H}), 2.56(\text{q, 2H}), 2.81(\text{bd, 1H}), 3.05(\text{m, 1H}), 3.58(\text{t, 1H}), 4.41(\text{d, 1H}), 5.38(\text{q, 1H}), 7.00\text{-7.40(m, 6H), 7.58(m, 2H).}$

30 Example 28: Synthesis of 5-methyl-6-ethyl-2-(N-methylphenyl-amino)-4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride

After N-methylaniline(0.44ml, 4.06mmol) was added to a mixed solution of 5-methyl-6-ethyl-4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)-2-chloropyrimidine(0.80g, 2.65mmol) and dimethylformamide(5ml), 0.60g of the titled compound was obtained in accordance with the same procedure as in Step 2

- 31 -

of Example 1.

Yield: 55.4%

M.P.: 214-216°C

<sup>1</sup>H-NMR(DMSO-d<sub>6</sub>): δ 1.90(t, 3H), 1.46(d, 3H), 2.18(s, 3H),

5 2.67(q, 2H), 2.79(bs, 2H), 2.90-3.18(m, 1H), 3.40-3.60(s+m, 4H), 4.18(dd, 1H), 5.25(q, 1H), 7.05-7.20(s, 4H), 7.32-7.58(m, 5H).

Example 29: Synthesis of 2-(2-methyl-4-fluorophenylamino)-  
10 4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)cyclopenta-  
[d]pyrimidine hydrochloride

Step 1: 2-Amino-4-hydroxycyclopenta[d]pyrimidine

15 A solution of 2-ethoxycarbonyl cyclopentanone (114ml, 0.77mol) and N,N-dimethylformamide (40ml) was added dropwise to a mixture solution of sodium methoxide(83.2g, 0.44mol) and N,N-dimethylformamide(80ml), while maintaining the temperature of the reaction system below 0°C. A solution of 20 guanidine HCl salt(81g, 0.85mol) and methanol(127ml) was added to the above reaction mixture and then was heated to reflux for 14 hours. The reaction mixture was neutralized by conc. HCl and the resulting solid was filtered and dried under reduced pressure to give 20.69g of titled compound.

25 (Yield: 18%)

Step 2: 2,4-Dihydroxycyclopenta[d]pyrimidine

To a mixture solution of 20% HCl(62ml) and 2-amino-30 4-hydroxycyclopenta[d]pyrimidine (20.6g, 0.136mol) prepared in the above Step 1 was added aqueous solution of sodium nitrite (19.4g) for 4 hours while keeping the temperature of the reaction system at 70°C. The reaction mixture was cooled to 0°C and the resulting solid was filtered, dried 35 under reduced pressure to give 15.43g of titled compound. (Yield: 74.6%)

- 32 -

Step 3: 2,4-dichlorocyclopenta[d]pyrimidine

A mixture solution of phosphorous oxychloride(49ml), N,N-dimethylaniline(8.0ml) and 2,4-dihydroxycyclopenta[d] 5 pyrimidine(15.4g, 0.1mol) prepared in the above Step 2 was heated to reflux for 3 hours and cooled to a room temperature. After the reaction mixture was diluted with dichloromethane, the diluted solution was added to ice water, while maintaining the temperature of the reaction 10 system below 10°C. The reaction mixture was extracted with dichloromethane, dried over anhydrous sodium sulfate and concentrated in vacuo to give 2.8g of titled compound as an oily form. (Yield: 15%)

15 Step 4: 4-(1-Methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)-2-chlorocyclopenta[d]pyrimidine

In accordance with the same procedure as in Step 1 of Example 1, except that 1-methyl-1,2,3,4-tetrahydroiso- 20 quinoline(1.7g, 11.55mmol) and 2,4-dichlorocyclopenta[d] pyrimidine(2.0g, 10.5mmol) prepared in the above Step 3 were used as starting materials, 1.95g of the title compound was prepared. (Yield: 62%)

25 Step 5: 2-(2-Methyl-4-fluorophenylamino)-4-(1-methyl-1,2, 3,4-tetrahydroisoquinolin-2-yl)cyclopenta[d]pyrimidine hydrochloride

After 4-fluoro-2-methylaniline(0.40ml, 3.60 mmol) was 30 added to a mixture solution of 4-(1-methyl-1,2,3,4-tetra hydroisoquinolin-2-yl)-2-chlorocyclopenta[d]pyrimidine (0.50g, 1.70mmol) and dimethylformamide(5ml), 0.15g of the titled compound was obtained in accordance with the same procedure as in Step 2 of Example 1.

35 Yield: 20.8%

M.P.: 110-112°C

<sup>1</sup>H-NMR(DMSO-d<sub>6</sub>): δ 1.50(t, 3H), 2.12(m, 2H), 2.25(s, 3H),

- 33 -

2.93(bd, 3H), 3.10(m, 2H), 3.42(bd, 2H), 3.70(bd, 1H), 4.40(bd, 1H), 5.78(bd, 1H), 7.22(m, 6H), 7.50(m, 5H), 7.60(m, 1H), 9.80(s, 1H), 13.32(bd, 1H).

5 Example 30: Synthesis of 2-(4-fluorophenylamino)-4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)cyclopenta[d]pyrimidine hydrochloride

After 4-fluoroaniline(0.40ml, 4.2mmol) was added to a  
10 mixture solution of 4-(1-methyl-1,2,3,4-tetrahydroiso-  
quinoline-2-yl)-2-chlorocyclopenta[d]pyrimidine(0.60g,  
2.0mmol) and dimethylformamide(5ml), 0.11g of the titled  
compound was obtained in accordance with the same procedure  
as in Step 2 of Example 1.

15 Yield: 13.4%

M.P.: 220-222°C

<sup>1</sup>H-NMR(DMSO-d<sub>6</sub>): δ 1.58(d, 3H), 2.10(bd, 2H), 3.01(bd, 4H),  
3.18(m, 2H), 3.60(bd, 1H), 4.45(bd, 1H), 5.64(bd, 1H),  
7.30(m, 6H), 7.62(m, 2H), 10.42(s, 1H), 13.15(bd, 1H).

20

Example 31: Synthesis of 2-(N-methylphenylamino)-4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)cyclopenta[d]pyrimidine hydrochloride

25 After N-methylaniline(0.20ml, 1.90mmol) was added to a  
mixture solution of 4-(1-methyl-1,2,3,4-tetrahydroiso-  
quinolin-2-yl)-2-chlorocyclopenta[d]pyrimidine (0.51g,  
1.70mmol) and dimethylformamide(5ml), 0.20g of the titled  
compound was obtained in accordance with the same procedure  
30 as in Step 2 of Example 1.

Yield: 29%

M.P.: 105-107°C

<sup>1</sup>H-NMR(DMSO-d<sub>6</sub>): δ 1.42(bd, 3H), 2.10(m, 2H), 2.87(m, 5H),  
3.10(m, 2H), 3.58(s, 3H), 4.38(bd, 1H), 5.53(q, 1H), 7.21(m,  
35 4H), 7.48(m, 5H), 12.62(bd, 1H).

Example 32: Synthesis of 2-(2-methyl-4-fluorophenylamino)-

- 34 -

4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)-5,6,7,8-tetrahydroquinazoline hydrochloride

Step 1: 2,4-Dihydroxy-5,6,7,8-tetrahydroquinazoline

5

A mixture solution of 2,4-dihydroxyquinazoline(39.2g, 0.24mol), platinum oxide(4g) and trifluoroacetic acid(300ml) was hydrogenated by Parr reactor for 2 hours. Platinum was filtered and the filtrate was concentrated, 10 diluted with water, and basified with 1N-NaOH solution. The resulting solid was filtered and dried to give 13.76g of the titled compound. (Yield: 34.5%)

Step 2: 2,4-Dichloro-5,6,7,8-tetrahydroquinazoline

15

2,4-Dihydroxy-5,6,7,8-tetrahydroquinazoline(3.4g, 20mmol) prepared in the above Step 1 was suspended in a mixture solution of phosphorous oxychloride(10mL) and N,N-dimethylaniline(0.8ml). The reaction mixture was heated 20 to reflux for 3 hours and cooled to room temperature. The reaction mixture was added to ice water while maintaining the temperature of the reaction system below 10°C and the resulting solid was filtered, dried under reduced pressure to give 3.26g of the titled compound.

25 (Yield: 80%)

Step 3: 4-(1-Methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)-2-chloro-5,6,7,8-tetrahydroquinazoline

30

A mixture solution of 1-methyl-1,2,3,4-tetrahydroisoquinoline(2.6g, 17.4mmol), triethylamine(2.8mL), N,N-dimethylformamide (20ml) and 2,4-dichloro-5,6,7,8-tetrahydroquinazoline(3.2g, 15.8mmol) prepared in the above Step 2 were stirred at 80°C for 3 hours and cooled. The reaction 35 mixture was diluted with ethyl acetate and washed with water. The organic layer was separated, dried over anhydrous sodium sulfate, and concentrated. The residue was purified

- 35 -

with silica gel column chromatography to give 3.1g of the titled compound. (Yield: 62.5%)

Step 4: 2-(2-Methyl-4-fluorophenylamino)-4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)-5,6,7,8-tetrahydroquinazoline hydrochloride

After 4-fluoro-2-methylaniline(0.60ml, 5.4mmol) was added to a mixture solution of 4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)-2-chloro-5,6,7,8-tetrahydroquinazoline(0.75g, 2.40mmol) and dimethylformamide(5ml), 0.58g of the titled compound was obtained in accordance with the same procedure as in Step 2 of Example 1.

Yield: 55%

M.P.: 190-193°C

$^1\text{H-NMR(DMSO-d}_6\text{)}$ :  $\delta$  1.53(d, 3H), 1.60-1.96(m, 3H), 2.34(s, 3H), 2.55(bd, 2H), 2.75(bd, 4H), 2.98(m, 1H), 3.54(m, 1H), 4.25(bd, 1H), 5.36(q, 1H), 7.12-7.31(m, 6H), 7.60(m, 1H), 9.69(s, 1H).

20

Example 33: Synthesis of 2-(N-methylphenylamino)-4-(1-methyl-1,2,3,4-tetrahydroisoquinoline-2-yl)-5,6,7,8-tetrahydroquinazoline hydrochloride

After N-methylaniline(0.50ml, 4.8mmol) was added to a mixture solution of 4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)-2-chloro-5,6,7,8-tetrahydroquinazoline(0.75g, 2.40mmol) and dimethylformamide(5ml), 0.26g of the titled compound was obtained in accordance with the same procedure as in Step 2 of Example 1.

Yield: 26%

M.P.: 207-210°C

$^1\text{H-NMR(DMSO-d}_6\text{)}$ :  $\delta$  1.42(d, 3H), 1.53-1.96(m, 3H), 2.57(bd, 1H), 2.80(m, 5H), 2.95(m, 1H), 3.45(bd, 1H), 3.60(s, 3H), 4.18(bd, 1H), 5.25(q, 1H), 7.16(m, 3H), 7.50(m, 6H), 12.10(s, 1H).

- 36 -

Example 34: Synthesis of 6-methyl-2-(2-methyl-4-fluoro-phenylamino)-4-(1,2,3,4-tetrahydroisoquinolin-2-yl)-pyrimidine hydrochloride

5 Step 1: 6-methyl-4-(1,2,3,4-tetrahydroisoquinolin-2-yl)-2-chloropyrimidine

In accordance with the same procedure as in Step 1 of Example 1, except that 6-methyl-2,4-dichloropyrimidine 10 (3.26g, 20mmol), 1,2,3,4-tetrahydroisoquinoline(2.6ml, 20.5mmol), triethylamine(3.4ml, 24.4mmol) and N,N-dimethyl formamide (10ml) were used as starting materials, 3.1g of the titled compound was prepared. (Yield: 59.7%)

15 Step 2: 6-Methyl-2-(2-methyl-4-fluorophenylamino)-4-(1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride

After 2-methyl-4-fluoroaniline(0.8ml, 7.2mmol) was added to a mixture solution of 6-methyl-4-(1,2,3,4-tetrahydroisoquinoline-2-yl)-2-chloropyrimidine(1.0g, 3.8mmol) and dimethylformamide(10ml), 0.85g of the titled compound was obtained in accordance with the same procedure as in Step 2 of Example 1.

Yield: 58%

25 M.P.: 183-185°C

$^1\text{H-NMR}(\text{CDCl}_3)$ :  $\delta$  2.41(s, 3H), 2.48(d, 3H), 2.88(t, 1H), 3.02(t, 1H), 3.75(t, 1H), 3.91(t, 1H), 4.67(s, 1H), 4.78(s, 1H), 6.00(d, 1H), 6.90-7.30(m, 5H), 7.58(m, 1H), 9.75(s, 1H), 14.20(bs, 1H).

30

Example 35: Synthesis of 6-methyl-2-(4-fluorophenyl-amino)-4-(1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride

35 After 4-fluoroaniline(0.7ml, 7.4mmol) was added to a mixture solution of 6-methyl-4-(1,2,3,4-tetrahydroisoquinoline-2-yl)-2-chloropyrimidine(1.0g, 3.8mmol) and

- 37 -

dimethylformamide(10ml), 0.6g of the titled compound was obtained in accordance with the same procedure as in Step 2 of Example 1.

Yield: 42.6%

5 M.P.: 238-240°C

$^1\text{H-NMR}(\text{CDCl}_3)$ :  $\delta$  2.45(d, 3H), 2.90-3.10(m, 2H), 3.78(t, 1H), 4.05(t, 1H), 4.70(s, 1H), 4.92(t, 1H), 6.05(d, 1H), 6.90-7.30(m, 6H), 7.60(m, 2H), 10.40(s, 1H), 13.80(bs, 1H).

10 Example 36: Synthesis of 6-methyl-2-(N-methylphenylamino)-4-(1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride

After N-methylaniline(0.61ml, 5.48mmol) was added to a mixture solution of 6-methyl-4-(1,2,3,4-tetrahydroisoquinolin-2-yl)-2-chloropyrimidine(0.95g, 3.65mmol) and dimethylformamide(10ml), 0.7g of the titled compound was obtained in accordance with the same procedure as in Step 2 of Example 1.

20 Yield: 52.3%

M.P.: 85-95°C

$^1\text{H-NMR}(\text{CDCl}_3)$ :  $\delta$  2.75(s, 3H), 2.99(s, 3H), 3.70(m, 2H), 3.87(s, 3H), 4.51(s, 1H), 4.65(s, 1H), 5.30(bs, 1H), 6.08(d, 1H), 6.88(d, 1H), 7.05-7.60(m, 8H), 13.05(s, 1H).

25

Example 37: Synthesis of 6-ethyl-2-(2-methyl-4-fluorophenylamino)-4-(1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride

30 Step 1: 6-Ethyl-4-(1,2,3,4-tetrahydroisoquinolin-2-yl)-2-chloropyrimidine

In accordance with the same procedure as in Step 1 of Example 1, except that 1,2,3,4-tetrahydroisoquinoline(3.5ml, 35 28mmol), triethylamine(3.9ml, 28mmol), N,N-dimethylformamide (20ml) and 6-ethyl-2,4-dichloropyrimidine(4.9g, 27.7mmol) prepared in Preparation 2 were used as starting materials,

- 38 -

5.0g of the titled compound was prepared. (Yield: 66%)

Step 2: 6-Ethyl-2-(2-methyl-4-fluorophenylamino)-4-(1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride

5

After 2-methyl-4-fluoroaniline(0.57ml, 5.13mmol) was added to a mixture solution of 6-ethyl-4-(1,2,3,4-tetrahydroisoquinoline-2-yl)-2-chloropyrimidine(0.7g, 2.56mmol) and dimethylformamide(5ml), 0.55g of the titled compound was obtained in accordance with the same procedure as in Step 2 of Example 1.

10

Yield: 54%

M.P.: 223-225°C

15  $^1\text{H-NMR}(\text{CDCl}_3)$ :  $\delta$  1.36(qq, 3H), 2.35(s, 3H), 2.69(tt, 2H), 2.90(tt, 2H), 3.77(tt, 2H), 4.66(ss, 2H), 5.93(d, 2H), 6.72-7.30(m, 6H), 7.50(dd, 1H), 9.80(s, 1H), 14.00(s, 1H).

20

Example 38: Synthesis of 6-ethyl-2-(4-fluorophenylamino)-4-(1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride

25

After 4-fluoroaniline(0.50ml, 5.28mmol) was added to a mixture solution of 6-ethyl-4-(1,2,3,4-tetrahydroisoquinoline-2-yl)-2-chloropyrimidine(0.7g, 2.56mmol) and dimethylformamide(5ml), 0.41g of the titled compound was obtained in accordance with the same procedure as in Step 2 of Example 1.

Yield: 42%

M.P.: 203-206°C

30

$^1\text{H-NMR}(\text{CDCl}_3)$ :  $\delta$  1.42(tt, 3H), 2.74(qq, 2H), 3.02(tt, 2H), 3.93(tt, 2H), 4.82(ss, 2H), 6.03(ss, 2H), 7.00-7.32(m, 6H), 7.54-7.64(m, 2H), 10.60(s, 1H), 13.80(s, 1H).

35

Example 39: Synthesis of 6-ethyl-2-(N-methylphenylamino)-4-(1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride

After N-methylaniline(0.54ml, 5.15mmol) was added to a

- 39 -

5 mixture solution of 6-ethyl-4-(1,2,3,4-tetrahydroisoquinoline-2-yl)-2-chloropyrimidine(0.7g, 2.56mmol) and dimethylformamide(5ml), 0.56g of the titled compound was obtained in accordance with the same procedure as in Step 2 of Example 1.

Yield: 57%

M.P.: 98-100°C

10  $^1\text{H-NMR}(\text{CDCl}_3)$ :  $\delta$  1.24-1.40(m, 3H), 2.83(tt, 2H), 3.16-3.24(m, 2H), 3.65(tt, 2H), 3.89(s, 3H), 4.53(ss, 2H), 6.00(ss, 1H), 6.85(d, 1H), 7.05-7.55(m, 8H), 13.40(s, 1H).

Example 40: Synthesis of 6-ethyl-2-(2-methylphenylamino)-4-(1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride

15 After 2-methylaniline(0.55ml, 5.15mmol) was added to a mixture solution of 6-ethyl-4-(1,2,3,4-tetrahydroisoquinoline-2-yl)-2-chloropyrimidine(0.7g, 2.56mmol) and dimethylformamide(5ml), 0.23g of the titled compound was obtained in accordance with the same procedure as in Step 2 of Example 1.

Yield: 24%

M.P.: 153-155°C

25  $^1\text{H-NMR}(\text{CDCl}_3)$ :  $\delta$  1.37-1.47(m, 3H), 2.50(s, 3H), 2.74-2.76(m, 2H), 2.97(tt, 2H), 3.87(tt, 2H), 4.76(ss, 2H), 5.98(ss, 1H), 7.10-7.28(m, 7H), 7.70(t, 1H), 9.82(s, 1H), 14.17(s, 1H).

Example 41: Synthesis of 5,6-dimethyl-2-(2-methyl-4-fluoro-phenylamino)-4-(1,2,3,4-tetrahydroisoquinolin-2-yl)-pyrimidine hydrochloride

30 Step 1: 5,6-dimethyl-4-(1,2,3,4-tetrahydroisoquinolin-2-yl)-2-chloropyrimidine

35 In accordance with the same procedure as in Step 1 of Example 1, except that 1,2,3,4-tetrahydroisoquinoline(2.9g, 23mmol) and 5,6-dimethyl-2,4-dichloropyrimidine(3.8g, 21mmol) and 1,2,3,4-tetrahydroisoquinoline(2.9g, 23mmol)

- 40 -

prepared in Step 1 of Example 12 were used as starting materials, 3.95g of the titled compound was prepared. (Yield: 68.7%)

5 Step 2: 5,6-Dimethyl-2-(2-methyl-4-fluorophenylamino)-4-(1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride

After 4-fluoro-2-methylaniline(0.8ml, 7mmol) was added to a mixture solution of 5,6-dimethyl-4-(1,2,3,4-tetrahydroisoquinoline-2-yl)-2-chloropyrimidine(1.0g, 3.6mmol) and dimethylformamide(10ml), 0.58g of the titled compound was obtained in accordance with the same procedure as in Step 2 of Example 1.

Yield: 44%

15 M.P.: 190-193°C

$^1\text{H-NMR(DMSO-d}_6\text{)}$ :  $\delta$  2.17(s, 3H), 2.30(s, 3H), 2.36(s, 3H), 2.90(t, 2H), 3.80(t, 1H), 4.75(s, 2H), 7.08-7.19(m, 6H), 7.70(m, 1H), 9.63(s, 1H), 13.62(s, 1H).

20 Example 42: Synthesis of 5,6-dimethyl-2-(4-fluorophenylamino)-4-(1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride

After 4-fluoroaniline(0.7ml, 7.4mmol) was added to a mixture solution of 5,6-dimethyl-4-(1,2,3,4-tetrahydroisoquinolin-2-yl)-2-chloropyrimidine(1.0g, 3.6mmol) and dimethylformamide(5ml), 0.67g of the titled compound was obtained in accordance with the same procedure as in Step 2 of Example 1.

30 Yield: 48%

M.P.: 251-253°C

$^1\text{H-NMR(DMSO-d}_6\text{)}$ :  $\delta$  2.23(s, 3H), 2.41(s, 3H), 3.02(t, 2H), 3.94(t, 2H), 4.87(s, 2H), 7.35(m, 6H), 7.65(m, 2H), 10.39(s, 1H), 13.20(bd, 1H).

35

Example 43: Synthesis of 5,6-dimethyl-2-(N-methylphenylamino)-4-(1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine

- 41 -

hydrochloride

After N-methylaniline(0.84ml, 7.8mmol) was added to a mixture solution of 5,6-dimethyl-4-(1,2,3,4-tetrahydroisoquinolin-2-yl)-2-chloropyrimidine(1.0g, 3.6mmol) and dimethylformamide(5ml), 0.55g of the titled compound was obtained in accordance with the same procedure as in Step 2 of Example 1.

Yield: 39%

10 M.P.: 58-60°C

$^1\text{H-NMR(DMSO-d}_6\text{)}: \delta$  2.14(s, 3H), 2.45(s, 3H), 2.83(t, 2H), 3.64(s, 3H), 3.71(t, 2H), 4.66(s, 2H), 7.07-7.15(m, 4H), 7.38-7.54(m, 5H), 12.40(s, 1H).

15 Example 44: Synthesis of 5-methyl-6-ethyl-2-(2-methyl-4-fluorophenylamino)-4-(1,2,3,4-tetrahydroisoquinolin-2-yl)-pyrimidine hydrochloride

Step 1: 5-Methyl-6-ethyl-4-(1,2,3,4-tetrahydroisoquinolin-2-yl)-2-chloropyrimidine

In accordance with the same procedure as in Step 1 of Example 1, except that 1,2,3,4-tetrahydroisoquinoline(3.5ml, 28mmol) and 2,4-dichloro-5-methyl-6-ethylpyrimidine(4.9g, 25 27.7mmol) prepared in Preparation 4 were used as starting materials, 5.0g of the titled compound was prepared.  
(Yield: 66%)

Step 2: 5-Methyl-6-ethyl-2-(2-methyl-4-fluorophenylamino)-4-(1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride

After 4-fluoro-2-methylaniline(0.5ml, 3.6mmol) was added to a mixture solution of 5-methyl-6-ethyl-4-(1,2,3,4-tetrahydroisoquinolin-2-yl)-2-chloropyrimidine(0.7g, 2.4mmol) and dimethylformamide(5ml), 0.53g of the titled compound was obtained in accordance with the same procedure

- 42 -

as in Step 2 of Example 1.

Yield: 53.5%

M.P.: 192-194°C

5  $^1\text{H-NMR}(\text{DMSO-d}_6)$ :  $\delta$  1.25(t, 3H), 2.19(s, 3H), 2.28(s, 3H),  
2.68(q, 2H), 2.88(t, 2H), 3.79(t, 2H), 4.75(s, 2H), 7.15(m,  
6H), 7.70(m, 1H), 9.80(s, 1H).

Example 45: Synthesis of 5-methyl-6-ethyl-2-(4-fluorophenyl-amino)-4-(1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine

10 hydrochloride

After 4-fluoroaniline(0.45ml, 3.6mmol) was added to a mixture solution of 5-methyl-6-ethyl-4-(1,2,3,4-tetrahydroisoquinolin-2-yl)-2-chloropyrimidine(0.7g, 2.4mmol) and 15 dimethylformamide(5ml), 0.50g of the titled compound was obtained in accordance with the same procedure as in Step 2 of Example 1.

Yield: 52.2%

M.P.: 235-238°C

20  $^1\text{H-NMR}(\text{CDCl}_3)$ :  $\delta$  1.42(t, 3H), 2.25(s, 3H), 2.76(q, 2H),  
3.04(t, 2H), 3.90(t, 2H), 4.80(s, 2H), 6.95-7.35(m, 6H),  
7.55(m, 2H), 10.50(s, 1H), 13.80(bd, 1H).

Example 46: Synthesis of 5-methyl-6-ethyl-2-(N-methylphenyl-amino)-4-(1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine  
25 hydrochloride

After N-methylaniline(0.40ml, 3.6mmol) was added to a mixture solution of 5-methyl-6-ethyl-4-(1,2,3,4-tetrahydroisoquinolin-2-yl)-2-chloropyrimidine(0.7g, 2.4mmol) and 30 dimethylformamide(5ml), 0.50g of the titled compound was obtained in accordance with the same procedure as in Step 2 of Example 1.

Yield: 52.7%

35 M.P.: 75-80°C

$^1\text{H-NMR}(\text{CDCl}_3)$ :  $\delta$  1.32(t, 3H), 2.15(s, 3H), 2.80(t, 2H),  
3.10(m, 2H), 3.60(m, 2H), 3.80(s, 3H), 4.48(s, 2H), 6.95(m,

- 43 -

2H), 7.05-7.70(m, 7H).

Example 47: Synthesis of 2-(2-methyl-4-fluorophenylamino)-4-(1,2,3,4-tetrahydroisoquinolin-2-yl)cyclopenta[d]pyrimidine hydrochloride

Step 1: 4-(1,2,3,4-Tetrahydroisoquinolin-2-yl)-2-chlorocyclopenta[d]pyrimidine

10 In accordance with the same procedure as in Step 1 of Example 1, except that 1,2,3,4-tetrahydroisoquinoline(0.5ml, 4mmol) and 2,4-dichlorocyclopenta[d]pyrimidine(0.79g, 4mmol) prepared in Step 3 of Example 29 were used as starting materials, 0.58g of the titled compound was prepared.

15 (Yield: 51%)

Step 2: 2-(2-Methyl-4-fluorophenylamino)-2-(1,2,3,4-tetrahydroisoquinolin-2-yl)cyclopenta[d]pyrimidine hydrochloride

20 After 4-fluoro-2-methylaniline(0.25ml, 2.20mmol) was added to a mixture solution of 4-(1,2,3,4-tetrahydroisoquinolin-2-yl)-4-chlorocyclopenta[d]pyrimidine(0.58g, 2.0mmol) and dimethylformamide(5ml), 0.34g of the titled compound was obtained in accordance with the same procedure  
25 as in Step 2 of Example 1.

Yield: 41.4%

M.P.: 170-172°C

<sup>1</sup>H-NMR(DMSO-d<sub>6</sub>): δ 2.06(m, 2H), 2.26(s, 3H), 2.90(m, 4H), 3.12(t, 2H), 3.97(t, 2H), 4.90(s, 2H), 7.11-7.21(m, 6H),  
30 9.78(s, 1H), 13.25(bd, 1H).

Example 48: Synthesis of 2-(2-methyl-4-fluorophenylamino)-4-(1,2,3,4-tetrahydroisoquinolin-2-yl)-5,6,7,8-tetrahydroquinazoline hydrochloride

35

Step 1: 4-(1,2,3,4-tetrahydroisoquinolin-2-yl)-2-chloro-5,6,7,8-tetrahydroquinazoline hydrochloride

- 44 -

In accordance with the same procedure as in Step 1 of Example 1, except that a mixture solution of 1,2,3,4-tetrahydroisoquinoline(2.8ml, 22mmol), triethylamine(3.4ml, 24mmol), N,N-dimethylformamide(10ml) and 2,4-dichloro-5,6, 5 7,8-tetrahydroquinazoline(4.0g, 20mmol) prepared in Step 2 of Example 32 were used as starting materials, 4.7g of the titled compound was prepared. (Yield: 78.4%)

Step 2: 2-(2-Methyl-4-fluorophenylamino)-4-(1,2,3,4-tetra 10 hydroisoquinolin-2-yl)-5,6,7,8-tetrahydroquinazoline hydrochloride

After 4-fluoro-2-methylaniline(0.75ml, 6.6mmol) was added to a mixture solution of 4-(1,2,3,4-tetrahydroiso 15 quinolin-2-yl)-2-chloro-5,6,7,8-tetrahydroquinazoline(0.90g, 3.0mmol) and dimethylformamide(5ml), 0.36g of the titled compound was obtained in accordance with the same procedure as in Step 2 of Example 1.

Yield: 28%

20 M.P.: 191-193°C

$^1\text{H-NMR(DMSO-d}_6\text{)}$ :  $\delta$  1.62-1.80(bd, 4H), 2.26(s, 3H), 2.65(bd, 4H), 2.88(t, 2H), 3.84(t, 2H), 4.78(s, 2H), 7.18(m, 6H), 7.67(m, 1H), 9.72(s, 1H), 13.40(bd, 1H).

25 Example 49: Synthesis of 2-(4-fluorophenylamino)-4-(1,2,3,4-tetrahydroisoquinolin-2-yl)-5,6,7,8-tetrahydroquinazoline hydrochloride

After 4-fluoroaniline(0.60ml, 6.3mmol) was added to a 30 mixture solution of 4-(1,2,3,4-tetrahydroisoquinolin-2-yl)-2-chloro-5,6,7,8-tetrahydroquinazoline(0.90g, 3.0mmol) and dimethylformamide(5ml), 0.62g of the titled compound was obtained in accordance with the same procedure as in Step 2 of Example 1.

35 Yield: 50%

M.P.: 215-218°C

$^1\text{H-NMR(DMSO-d}_6\text{)}$ :  $\delta$  1.62-1.74(bd, 4H), 2.68(m, 4H), 2.95(t,

- 45 -

2H), 3.90(t, 2H), 4.86(s, 2H), 7.19-7.41(m, 6H), 7.57(m, 2H), 10.42(s, 1H), 11.40(bd, 1H).

5 Example 50: Synthesis of 2-(N-methylphenylamino)-4-(1,2,3,4-  
tetrahydroisoquinolin-2-yl)-5,6,7,8-tetrahydroquinazoline  
hydrochloride

After N-methylaniline(0.70ml, 6.3mmol) was added to a mixture solution of 4-(1,2,3,4-tetrahydroisoquinolin-2-yl)-  
10 2-chloro-5,6,7,8-tetrahydroquinazoline(0.90g, 3.0mmol) and dimethylformamide(5ml), 0.48g of the titled compound was obtained in accordance with the same procedure as in Step 2 of Example 1.

Yield: 39%

15 M.P.: 164-167°C

<sup>1</sup>H-NMR(DMSO-d<sub>6</sub>): δ 1.59-1.74(bd, 4H), 2.64(t, 2H), 2.78(m, 4H), 3.51(s, 3H), 3.78(t, 2H), 4.72(s, 2H), 7.19-7.17(m, 4H), 7.38-7.50(m, 5H), 12.18(bd, 1H).

20 Example 51: Synthesis of 2-(2-methylphenylamino)-4-(1,2,3,4-  
tetrahydroisoquinolin-2-yl)-5,6,7,8-tetrahydroquinazoline  
hydrochloride

After 2-methylaniline(0.30ml, 2.7mmol) was added to a mixture solution of 4-(1,2,3,4-tetrahydroisoquinolin-2-yl)-  
25 2-chloro-5,6,7,8-tetrahydroquinazoline(0.75g, 2.5mmol) and dimethylformamide(5ml), 0.50g of the titled compound was obtained in accordance with the same procedure as in Step 2 of Example 1.

30 Yield: 49%

M.P.: 173-175°C

<sup>1</sup>H-NMR(DMSO-d<sub>6</sub>): δ 1.63-1.77(bd, 4H), 2.32(s, 3H), 2.65(m, 4H), 2.88(t, 2H), 3.85(t, 2H), 4.80(s, 2H), 7.09-7.32(m, 7H), 7.72(m, 1H), 9.67(s, 1H), 13.43(bd, 1H).

35

Example 52: Synthesis of 6-methyl-2-(2-methyl-4-fluoro-  
phenylamino)-4-(7-methyl-4,5,6,7-tetrahydrothieno[2,3-c]-

- 46 -

pyridin-6-yl)pyrimidine hydrochloride

Step 1: 6-Methyl-4-(7-methyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridin-6-yl)-2-chloropyrimidine

5

In accordance with the same procedure as in Step 1 of Example 1, except that 2,4-dichloro-6-methylpyrimidine(3.1g, 19mmol) and 7-methyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridine (2.9g, 19mmol) in Preparation 1 were used as starting 10 materials, 2.2g of the titled compound was obtained as white crystal. (Yield: 41%)

Step 2: 6-Methyl-2-(2-methyl-4-fluorophenylamino)-4-(7-methyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridin-6-yl)-15 pyrimidine hydrochloride

After 4-fluoro-2-methylaniline(0.5ml, 4.6mmol) was added to a mixture solution of 6-methyl-4-(7-methyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridin-6-yl)-2-chloropyrimidine(0. 20 7g, 2.5mmol) and dimethylformamide(10ml), 0.45g of the titled compound was obtained in accordance with the same procedure as in Step 2 of Example 1.

Yield: 44.4%

M.P.: 120-121°C

25  $^1\text{H-NMR}(\text{CDCl}_3)$ :  $\delta$  1.54(dd, 3H), 2.40(s, 3H), 2.48(s, 3H), 2.68(m, 1H), 2.80(m, 1H), 3.30(mm, 1H), 4.45(dd, 1H), 5.48(qq, 1H), 6.02(d, 1H), 6.78(m, 1H), 6.95(m, 2H), 7.20(t, 1H), 7.50(m, 1H), 9.80(s, 1H), 14.20(bs, 1H).

30 Example 53: Synthesis of 6-methyl-4-(7-methyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridin-6-yl)-2-(4-fluorophenylamino)-pyrimidine hydrochloride

35 After 4-fluoroaniline(0.4ml, 3.7mmol) was added to a mixture solution of 6-methyl-4-(7-methyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridin-6-yl)-2-chloropyrimidine(0.7g, 2.5mmol) and dimethylformamide(10ml), 0.7g of the titled compound was

- 47 -

obtained in accordance with the same procedure as in Step 2 of Example 1.

Yield: 71.6%

M.P.: 210-212°C

5  $^1\text{H-NMR}(\text{CDCl}_3)$ :  $\delta$  1.80(dd, 3H), 2.42(s, 3H), 2.80(m, 2H), 3.40(mm, 1H), 4.60(dd, 1H), 5.60(mm, 1H), 6.08(d, 1H), 6.80(m, 1H), 7.08(t, 2H), 7.21(m, 1H), 7.55(m, 2H), 10.40(s, 1H), 13.80(s, 1H).

10 Example 54: Synthesis of 6-methyl-2-(N-methylphenylamino)-4-(7-methyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridin-6-yl)-pyrimidine hydrochloride

15 After N-methylaniline(0.45ml, 4.05mmol) was added to a mixture solution of 6-methyl-4-(7-methyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridin-6-yl)-2-chloropyrimidine(0.75g, 2.7mmol) and dimethylformamide(10ml), 0.52g of the titled compound was obtained in accordance with the same procedure as in Step 2 of Example 1.

20 Yield: 49.7%

M.P.: 175-178°C

25  $^1\text{H-NMR}(\text{CDCl}_3)$ :  $\delta$  1.38(dd, 3H), 2.50(bs, 1H), 2.68-3.05(m, 4H), 3.45(m, 1H), 3.90(s, 3H), 4.27(dd, 1H), 5.30(qq, 1H), 6.02(d, 1H), 6.78(d, 1H), 7.10-7.35(m, 4H), 7.38-7.55(m, 2H), 13.50 (bs, 1H).

Example 55: Synthesis of 5,6-dimethyl-2-(2-methyl-4-fluoro-phenylamino)-4-(7-methyl-4,5,6,7-tetrahydrothieno[2,3-c]-pyridin-6-yl)pyrimidine hydrochloride

30

Step 1: 5,6-Dimethyl-4-(7-methyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridin-6-yl)-2-chloropyrimidine

35 In accordance with the same procedure as in Step 1 of Example 1, except that N,N-dimethylformamide(20ml), 5,6-dimethyl-2,4-dichloropyrimidine(2.8g, 16mmol) prepared in Step 1 of Example 12 and 7-methyl-4,5,6,7-tetrahydro

- 48 -

thieno[2,3-c]pyridine (2.7g, 17.6mmol) in Preparation 2 were used as starting materials, 1.85g of the titled compound was prepared. (Yield: 39.4%)

5 Step 2: 5,6-Dimethyl-2-(2-methyl-4-fluorophenylamino)-4-(7-methyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridin-6-yl)pyrimidine hydrochloride

After 4-fluoro-2-methylaniline(0.5ml, 4.6mmol) was 10 added to a mixture solution of 5,6-dimethyl-4-(7-methyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridin-6-yl)-2-chloropyrimidine(0.68g, 2.3mmol) and dimethylformamide(5ml), 0.12g of the titled compound was obtained in accordance with the same procedure as in Step 2 of Example 1.

15 Yield: 12.4%

M.P.: >240°C

<sup>1</sup>H-NMR(CDCl<sub>3</sub>): δ 1.60(d, 3H), 2.22(s, 3H), 2.43(s, 3H), 2.55(s, 1H), 2.72(bd, 1H), 2.80(m, 1H), 3.48(m, 1H), 4.30(m, 1H), 5.58(q, 1H), 6.76(d, 1H), 6.90(m, 2H), 7.18(d, 1H), 20 7.44(m, 1H), 9.55(s, 1H), 14.36(s, 1H).

Example 56: Synthesis of 5-methyl-2-(2-methyl-4-fluorophenylamino)-4-(7-methyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridin-6-yl)-6-ethylpyrimidine hydrochloride

25

Step 1: 5-Methyl-4-(7-methyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridin-6-yl)-6-ethyl-2-chloropyrimidine

In accordance with the same procedure as in Step 1 of 30 Example 1, except that triethylamine(2.2ml), N,N-dimethyl formamide(20ml), 2,4-dichloro-5-methyl-6-ethylpyrimidine (2.7g, 14.1mmol) prepared in Preparation 4 and 7-methyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridine(2.4g, 15.7mmol) prepared in Preparation 1 were used as starting materials, 35 2.23g of the titled compound was prepared. (Yield: 51.3%)

Step 2: 5-Methyl-2-(2-methyl-4-fluorophenylamino)-4-

- 49 -

(7-methyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridin-6-yl)-6-ethylpyrimidine hydrochloride

After 4-fluoro-2-methylaniline(0.51ml, 4.59mmol) was  
5 added to a mixture solution of 5-methyl-4-(7-methyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridin-6-yl)-6-ethyl-2-chloropyrimidine(0.74g, 2.4mmol) and dimethylformamide(5ml), 0.15g of the titled compound was obtained in accordance with the same procedure as in Step 2 of Example 1.

10 Yield: 14.4%

M.P.: 178-180°C

<sup>1</sup>H-NMR(DMSO-d<sub>6</sub> + TFA): δ 1.07(t, 3H), 1.75(d, 3H), 1.95(s, 3H), 2.21(s, 3H), 2.35(m, 2H), 2.61(q, 2H), 3.34(m, 2H), 5.05(m, 1H), 6.81(d, 1H), 6.83-7.20(m, 3H), 7.50(d, 1H).

15

Example 57: Synthesis of 6-methyl-4-(2-methyl-4-fluoro-phenylamino)-2-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride

20 Step 1: 6-Methyl-2-chloro-4-hydroxypyrimidine

To a mixture solution of 6-methyl-2,4-dichloropyrimidine (25g, 0.153mol) in tetrahydrofuran(170ml) was added 1N-NaOH solution(420ml) and stirred for 48 hours at 25 room temperature. The reaction mixture was washed with ethyl ether to remove impurities, acidified with hydrochloric acid, and then extracted with ethyl acetate. The ethyl acetate layer was dried over anhydrous sodium sulfate, concentrated under reduced pressure to give 13.5g 30 of titled compound as yellow solid form. (Yield: 66.7%)

Step 2: 6-Methyl-2-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)-4-hydroxypyrimidine

35 A mixture solution of 6-methyl-2-chloro-4-hydroxypyrimidine(6g, 37.5mmol) prepared in the above Step 1, 1-methyl-1,2,3,4-tetrahydroisoquinoline(11.6g, 78.8mmol) and

- 50 -

N,N-dimethylformamide(30ml) was stirred at 120 for 2 hours and cooled to give a solid. The resulting solid was dissolved in a mixture solution of dichloromethane and methanol and the undissolved materials were filtered off.

5 The filtrate residue was washed many times with water, dried over anhydrous sodium sulfate, concentrated under reduced pressure to give 7.1g of titled compound. (Yield: 74.1%)

Step 3: 6-Methyl-2-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)-4-chloropyrimidine

10 A mixture solution of 6-methyl-2-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)-4-hydroxypyrimidine(7.0g, 27.4mmol) prepared in the above Step 2, phosphorous oxychloride(30ml) and N,N-dimethylaniline(2.3ml) was stirred 15 at 90°C for 2 hours and cooled. The reaction mixture was added to ice water and basified with sodium bicarbonate and then was extracted with ethyl ether. The ethyl ether layer was dried over anhydrous sodium sulfate, and concentrated 20 under reduced pressure to give 4.5g of titled compound. (Yield: 60%)

Step 4: 6-Methyl-4-(2-methyl-4-fluorophenylamino)-2-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride

25 2-Methyl-4-fluoroaniline(1.1ml, 10.2mmol) was added to a mixture solution of 6-methyl-2-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)-4-chloropyrimidine(1.5g, 5.5mmol) and dimethylformamide(10ml). The reaction solution was stirred 30 for 3 hours and cooled to room temperature. The reaction mixture was diluted with dichloromethane and washed with water. Dichloromethane layer was separated, basified with aqueous sodium hydroxide solution, washed with water, and 35 dried and concentrated in vacuo. The resulting residue was purified with silica gel column chromatography to give a free base form of titled compound as an oily form. The free

- 51 -

base form of titled compound was dissolved in ethyl ether, then hydrochloric acid was added thereto. The resulting solid was filtered, dried under reduced pressure to give 0.9g of titled compound.

5 Yield: 41%

M.P.: 157-160°C

<sup>1</sup>H-NMR(DMSO-d<sub>6</sub>): δ 1.42(bs, 3H), 2.25(s, 3H), 2.40(s, 3H), 2.90(bs, 2H), 3.55(bs, 1H), 4.40(bs, 1H), 5.60(bs, 1H), 6.40(s, 1H), 7.00-7.30(m, 6H), 7.40(bs, 1H), 10.60(bs, 1H),  
10 12.35(bs, 1H).

Example 58: Synthesis of 6-methyl-4-(4-fluorophenylamino)-2-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride

15

After 4-fluoroaniline(0.8ml, 8.4mmol) was added to a mixture solution of 6-methyl-2-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)-4-chloropyrimidine(1.5g, 5.5mmol) and dimethylformamide(10ml), 1.1g of the titled compound was obtained in accordance with the same procedure as in Step 4 of Example 57.

20 Yield: 52%

M.P.: 165-167°C

<sup>1</sup>H-NMR(DMSO-d<sub>6</sub>): δ 1.58(d, 3H), 2.50(s, 3H), 3.00(bs, 2H),  
25 3.60(bs, 1H), 4.50(bs, 1H), 5.75(bs, 1H), 6.38(bs, 1H),  
7.00-7.50(m, 6H), 7.75(bs, 2H), 11.20(bs, 1H), 12.38(bs, 1H).

Example 59: Synthesis of 6-methyl-4-(2-methyl-4-fluoro-

30 phenylamino)-2-(7-methyl-4,5,6,7-tetrahydrothieno[2,3-c]-pyridin-6-yl)pyrimidine hydrochloride

Step 1: 6-Methyl-2-(7-methyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridin-6-yl)-4-hydroxypyrimidine

35

In accordance with the same procedure as in Step 2 of Example 57, except that 6-methyl-2-chloro-4-hydroxy-

- 52 -

pyrimidine(6g, 37.5mmol) prepared in Step 1 of Example 57, and 7-methyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridine (12.07g, 78.75mmol) prepared in preparation 1 were used as starting materials, 6.9g of the titled compound was 5 prepared.

(Yield: 70%)

**Step 2: 6-Methyl-2-(7-methyl-4,5,6,7-tetrahydrothieno-[2,3-c]pyridine-6-yl)-4-chloropyrimidine**

10

In accordance with the same procedure as in Step 3 of Example 57, except that 6-methyl-2-(7-methyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridin-6-yl)-4-hydroxypyrimidine(6.5g, 24.9mmol) prepared in the above Step 1 was used as a 15 starting material, 4.5g of the titled compound was prepared. (Yield: 70%)

**Step 3: 6-Methyl-4-(2-methyl-4-fluorophenylamino)-2-(7-methyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridin-6-yl)-20 pyrimidine hydrochloride**

After 2-methyl-4-fluoroaniline(0.38ml, 3.42mmol) was added to a mixture solution of 6-methyl-2-(7-methyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridin-6-yl)-4-chloropyrimidine 25 (0.5g, 1.8mmol) and dimethylformamide(10ml), 0.35g of the titled compound was obtained in accordance with the same procedure as in Step 4 of Example 57.

Yield: 48%

M.P.: 135-137°C

30  $^1\text{H-NMR}(\text{CDCl}_3)$ :  $\delta$  1.43(bs, 3H), 2.22(s, 3H), 2.42(s, 3H), 2.70(bs, 2H), 3.36(bs, 1H), 4.65(m, 1H), 5.70(m, 1H), 6.38(bs, 1H), 6.85(d, 1H), 7.04-7.30(m, 2H), 7.34-7.50(m, 2H), 10.58(bs, 1H), 12.42(bs, 1H).

35 Example 60: Synthesis of 6-methyl-4-(4-fluorophenylamino)-2-(7-methyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridin-6-yl)-pyrimidine hydrochloride

- 53 -

After 4-fluoroaniline(0.26ml, 2.74mmol) was added to a mixture solution of 6-methyl-2-(7-methyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridin-6-yl)-4-chloropyrimidine(0.5g, 1.8mmol) and dimethylformamide(10ml), 0.30g of the titled compound 5 was obtained in accordance with the same procedure as in Step 4 of Example 57.

Yield: 42.6%

M.P.: 245-247°C

<sup>1</sup>H-NMR(DMSO-d<sub>6</sub>): δ 1.58(d, 3H), 2.42(s, 3H), 2.81(m, 2H), 10 3.48(m, 1H), 4.64(m, 1H), 5.75(m, 1H), 6.25(s, 1H), 6.90(d, 1H), 7.30(t, 3H), 7.42(d, 2H), 7.70(m, 2H).

Example 61: Synthesis of 6-ethyl-2-(2-methyl-4-fluorophenyl-amino)-4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)-15 pyrimidine hydrochloride

**Step 1: 6-ethyl-2-chloro-4-hydroxypyrimidine**

In accordance with the same procedure as in Step 1 of 20 Example 57, except that 6-ethyl-2,4-dichloropyrimidine (27.08g, 0.153mol) prepared in Preparation 2 was used as a starting material, 14.6g of the titled compound was prepared. (Yield: 66.7%)

25 **Step 2: 6-Ethyl-2-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)-4-hydroxypyrimidine**

In accordance with the same procedure as in Step 2 of 30 Example 57, except that 6-ethyl-2-chloro-4-hydroxypyrimidine (7.0g, 37.5mmol) prepared in the above Step 1 and 1-methyl-1,2,3,4-tetrahydroisoquinoline(11.04g, 75mmol) were used as starting materials, 8.1g of the titled compound was prepared. (Yield: 80%)

35 **Step 3: 6-Ethyl-2-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)-4-chloropyrimidine**

- 54 -

In accordance with the same procedure as in Step 3 of Example 57, except that 6-ethyl-2-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)-4-hydroxypyrimidine(8.0g, 29.7mmol) prepared in the above Step 2 was used as a starting material, 4.9g of the titled compound was prepared. (Yield: 57.3%)

Step 4: 6-Ethyl-4-(2-methyl-4-fluorophenylamino)-2-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride

After 2-methyl-4-fluoroaniline(1.1ml, 10.2mmol) was added to a mixture solution of 6-ethyl-2-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)-4-chloropyrimidine(2.0g, 7.0mmol) and dimethylformamide(10ml), 1.1g of the titled compound was obtained in accordance with the same procedure as in Step 4 of Example 57.

Yield: 38%

M.P.: 123-125°C

<sup>20</sup> <sup>1</sup>H-NMR(DMSO-d<sub>6</sub>): δ 1.16-1.57(m, 6H), 2.27(s, 3H), 2.77-2.94(m, 4H), 3.50(bs, 1H), 4.40(bs, 1H), 5.63(bs, 1H), 6.45(s, 1H), 7.08-7.52(m, 7H), 10.61(s, 1H), 12.27(s, 1H).

Example 62: Synthesis of 6-ethyl-4-(2-methyl-4-fluorophenylamino)-2-(1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride

Step 1: 6-Ethyl-2-(1,2,3,4-tetrahydroisoquinolin-2-yl)-4-hydroxypyrimidine

<sup>30</sup> In accordance with the same procedure as in Step 2 of Example 57, except that 6-ethyl-2-chloro-4-hydroxypyrimidine(7.0g, 37.5mmol) prepared in Step 1 of Example 59 and 1,2,3,4-tetrahydroisoquinoline(9.4ml, 75mmol) were used as starting materials, 8.1g of the titled compound was prepared. (Yield: 84.6%)

- 55 -

Step 2: 6-Ethyl-2-(1,2,3,4-tetrahydroisoquinolin-2-yl)-4-chloropyrimidine

In accordance with the same procedure as in Step 2 of Example 57, except that 6-ethyl-2-(1,2,3,4-tetrahydroisoquinoline-2-yl)-4-hydroxypyrimidine(8.0g, 31.3mmol) prepared in the above Step 1 was used as a starting material, 4.7g of the titled compound was prepared. (Yield: 55%)

10 Step 3: 6-Ethyl-4-(2-methyl-4-fluorophenylamino)-2-(1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride

After 2-methyl-4-fluoroaniline(0.35ml, 3.15mmol) was added to a mixture solution of 6-ethyl-2-(1,2,3,4-tetrahydroisoquinolin-2-yl)-4-chloropyrimidine(0.40g, 1.46mmol) and dimethylformamide(10ml), 0.51g of the titled compound was obtained in accordance with the same procedure as in Step 4 of Example 57.

Yield: 88%

20 M.P.: 122-124°C

<sup>1</sup>H-NMR(DMSO-d<sub>6</sub>): δ 1.30(q, 3H), 2.24(s, 3H), 2.74-2.95(m, 4H), 3.88(t, 2H), 4.83(s, 2H), 6.44(s, 1H), 7.05-7.55(m, 7H), 10.62(s, 1H), 12.30(s, 1H).

25 Example 63: Synthesis of 6-ethyl-4-(4-fluorophenylamino)-2-(1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride

After 4-fluoroaniline(0.30ml, 3.17mmol) was added to a mixture solution of 6-ethyl-2-(1,2,3,4-tetrahydroisoquinolin-2-yl)-4-chloropyrimidine(0.40g, 1.46mmol) and dimethylformamide(10ml), 0.44g of the titled compound was obtained in accordance with the same procedure as in Step 4 of Example 57.

Yield: 78%

35 M.P.: 124-126°C

<sup>1</sup>H-NMR(CDCl<sub>3</sub>): δ 1.41(q, 3H), 2.70-2.95(m, 4H), 4.05(bs, 2H), 4.95(s, 2H), 6.16(s, 1H), 6.35-6.80(t, 2H), 7.04-7.14(m,

- 56 -

4H), 7.66-7.75(dd, 2H), 11.05(s, 1H), 12.06(s, 1H).

Example 64: Synthesis of 6-ethyl-4-(N-methylphenylamino)-2-(1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride

5

After N-methylaniline(0.10ml, 9.22mmol) was added to a mixture solution of 6-ethyl-2-(1,2,3,4-tetrahydroisoquinolin-2-yl)-4-chloropyrimidine(1.20g, 4.38mmol) and dimethylformamide(10ml), 0.22g of the titled compound was obtained in accordance with the same procedure as in Step 4 of Example 57.

10 Yield: 13%  
M.P.: 130-132°C  
15  $^1\text{H-NMR}(\text{CDCl}_3)$ :  $\delta$  1.15(t, 3H), 2.97-3.15(m, 4H), 3.55(s, 3H),  
7.50-7.60(m, 3H), 13.40(s, 1H).

Example 65: Synthesis of 5,6-dimethyl-4-(2-methyl-4-fluoro-phenylamino)-2-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride

Step 1: 5,6-Dimethyl-2,4-dichloropyrimidine

20 A mixture solution of 5,6-dimethyl-2,4-dihydroxy pyrimidine(72g, 0.51mol), phosphorous oxychloride(250ml) and N,N-dimethylaniline(41ml) was heated to reflux for 3 hours and cooled to room temperature. The reaction mixture was added to ice water and the resulting solid was filtered and recrystallized from dichloromethane to give 58.5g of the 30 titled compound. (Yield: 64.7%)

Step 2: 5,6-Dimethyl-2-chloro-4-hydroxypyrimidine

35 In accordance with the same procedure as in Step 1 of Example 57, except that 5,6-dimethyl-2,4-dichloropyrimidine (50.0g, 0.28mol) prepared in the above Step 1 was used as a starting material, 24.4g of the titled compound was

- 57 -

prepared. (Yield: 55%)

Step 3: 5,6-Dimethyl-2-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)-4-hydroxypyrimidine

5

In accordance with the same procedure as in Step 2 of Example 57, except that 5,6-dimethyl-2-chloro-4-hydroxypyrimidine(6.0g, 37.8mmol) prepared in the above Step 2 was used as a starting material, 7.6g of the titled compound was 10 prepared. (Yield: 75%)

Step 4: 5,6-Dimethyl-2-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)-4-chloropyrimidine

15

In accordance with the same procedure as in Step 3 of Example 57, except that 5,6-dimethyl-2-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)-4-hydroxypyrimidine(7.0g, 26mmol) prepared in the above Step 3 was used as starting material, 3.9g of the titled compound was prepared.

20 (Yield: 52%)

Step 5: 5,6-Dimethyl-4-(2-methyl-4-fluorophenylamino)-2-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride

25

After 2-methyl-4-fluoroaniline(0.7ml, 6.3mmol) was added to a mixture solution of 5,6-dimethyl-2-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)-4-chloropyrimidine(0.8 5g, 3.0mmol) and dimethylformamide(10ml), 0.9g of the titled 30 compound was obtained in accordance with the same procedure as in Step 4 of Example 57.

Yield: 72.6%

M.P.: 208-211°C

<sup>1</sup>H-NMR(DMSO-d<sub>6</sub>): δ 1.28(d, 3H), 2.16(s, 3H), 2.18(s, 3H),

35 2.55(s, 3H), 2.80(bd, 2H), 3.42(bd, 1H), 4.34(bd, 1H), 5.44(bd, 1H), 7.02(bd, 1H), 7.24(m, 6H), 9.65(s, 1H), 12.30(bd, 1H).

- 58 -

Example 66: Synthesis of (R)-5,6-dimethyl-4-(2-methyl-4-fluorophenylamino)-2-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride

5 Step 1: (R)-5,6-Dimethyl-2-(1-methyl-1,2,3,4-tetrahydroisoquinoline-2-yl)-4-hydroxypyrimidine

In accordance with the same procedure as in Step 2 of Example 57, except that 5,6-dimethyl-2-chloro-4-hydroxypyrimidine(6.0g, 37.8mmol) prepared in Example 60 and (R)-1-methyl-1,2,3,4-tetrahydroisoquinoline(11.7g, 79.5mmol) were used as starting materials, 7.0g of the titled compound was prepared. (Yield: 68.8%)

15 Step 2: (R)-5,6-Dimethyl-2-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)-4-chloropyrimidine

In accordance with the same procedure as in Step 3 of Example 57, except that (R)-5,6-dimethyl-2-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)-4-hydroxypyrimidine(7.0g, 26mmol) prepared in the above Step 1 was used as a starting material, 3.2g of the titled compound was prepared. (Yield: 42.8%)

25 Step 3: (R)-5,6-Dimethyl-4-(2-methyl-4-fluorophenylamino)-2-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride

After 2-methyl-4-fluoroaniline(0.82ml, 7.35mmol) was added to a mixture solution of (R)-5,6-dimethyl-2-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)-4-chloropyrimidine(1.0g, 3.5mmol) prepared in the above Step 2 and dimethylformamide(10ml), 1.2g of the titled compound was obtained in accordance with the same procedure as in Step 4 of Example 57.

Yield: 83%

M.P.: 207-209°C

- 59 -

<sup>1</sup>H-NMR(DMSO-d<sub>6</sub>): δ 1.28(d, 3H), 2.16(s, 3H), 2.18(s, 3H), 2.55(s, 3H), 2.80(bd, 2H), 3.42(bd, 1H), 4.34(bd, 1H), 5.44(bd, 1H), 7.02(bd, 1H), 7.24(m, 6H), 9.65(s, 1H), 12.30(bd, 1H).

5

Example 67: Synthesis of (S)-5,6-dimethyl-4-(2-methyl-4-fluorophenylamino)-2-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride

10 Step 1: (S)-5,6-Dimethyl-2-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)-4-hydroxypyrimidine

In accordance with the same procedure as in Step 2 of Example 57, except that 5,6-dimethyl-2-chloro-4-hydroxypyrimidine(6.0g, 37.8mmol) prepared in Example 60 and (S)-1-methyl-1,2,3,4-tetrahydroisoquinoline(11.7g, 79.5mmol) were used as starting materials, 6.6g of the titled compound was prepared. (Yield: 64.8%)

20 Step 2: (S)-5,6-Dimethyl-2-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)-4-chloropyrimidine

In accordance with the same procedure as in Step 2 of Example 57, except that (S)-5,6-dimethyl-2-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)-4-hydroxypyrimidine(7.0g, 26mmol) prepared in the above Step 1 was used as a starting material, 3.5g of the titled compound was prepared. (Yield: 46.8%)

30 Step 3: (S)-5,6-Dimethyl-4-(2-methyl-4-fluorophenylamino)-2-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride

After 2-methyl-4-fluoroaniline(0.82ml, 7.35mmol) was added to a mixture solution of (S)-5,6-dimethyl-2-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)-4-chloropyrimidine(1.0g, 3.5mmol) obtained in the above Step 2 and dimethylformamide

- 60 -

(10ml), 1.0g of the titled compound was obtained in accordance with the same procedure as in Step 4 of Example 57.

Yield: 69.2%

5 M.P.: 208-210°C

$^1\text{H-NMR(DMSO-d}_6\text{)}$ :  $\delta$  1.28(d, 3H), 2.16(s, 3H), 2.18(s, 3H), 2.55(s, 3H), 2.80(bd, 2H), 3.42(bd, 1H), 4.34(bd, 1H), 5.44(bd, 1H), 7.02(bd, 1H), 7.24(m, 6H), 9.65(s, 1H), 12.30(bd, 1H).

10

Example 68: Synthesis of 5,6-dimethyl-4-(4-fluorophenyl-amino)-2-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)-pyrimidine hydrochloride

15 After 4-fluoroaniline(0.6ml, 6.3mmol) was added to a mixture solution of 5,6-dimethyl-2-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)-4-chloropyrimidine(0.85g, 3.0mmol) and dimethylformamide(10ml), 0.62g of the titled compound was obtained in accordance with the same procedure as in 20 Step 4 of Example 57.

Yield: 52%

M.P.: 246-250°C

25  $^1\text{H-NMR(DMSO-d}_6\text{)}$ :  $\delta$  1.40(d, 3H), 2.18(s, 3H), 2.50(s, 3H), 2.88(bd, 2H), 3.42(bd, 1H), 4.42(bd, 1H), 5.62(bd, 1H), 7.18(m, 4H), 7.30(t, 2H), 7.63(q, 2H), 9.70(s, 1H), 12.30(bd, 1H).

Example 69: Synthesis of (R)-5,6-dimethyl-4-(4-fluorophenyl-amino)-2-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)-pyrimidine hydrochloride

30 After 4-fluoroaniline(0.6ml, 6.3mmol) was added to a mixture solution of (R)-5,6-dimethyl-2-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)-4-chloropyrimidine(0.85g, 3.0mmol) prepared in Step 2 of Example 61 and dimethylformamide(10ml), 0.50g of the titled compound was obtained in accordance with the same procedure as in Step 4

of Example 57.

Yield: 41.8%

M.P.: 245-248°C

<sup>1</sup>H-NMR(DMSO-d<sub>6</sub>): δ 1.40(d, 3H), 2.18(s, 3H), 2.50(s, 3H),

5 2.88(bd, 2H), 3.42(bd, 1H), 4.42(bd, 1H), 5.62(bd, 1H),  
7.18(m, 4H), 7.30(t, 2H), 7.63(q, 2H), 9.70(s, 1H),  
12.30(bd, 1H).

Example 70: Synthesis of (S)-5,6-dimethyl-4-(4-fluorophenyl-  
10 amino)-2-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)-  
pyrimidine hydrochloride

After 4-fluoroaniline(0.6ml, 6.3mmol) was added to a mixture solution of (S)-5,6-dimethyl-2-(1-methyl-1,2,3,4-tetrahydroisoquinoline-2-yl)-4-chloropyrimidine(0.85g, 3.0mmol) prepared in Step 2 of Example 62 and dimethylformamide (10ml), 0.55g of the titled compound was obtained in accordance with the same procedure as in Step 4 of Example 57.

20 Yield: 46%

M.P.: 245-247°C

<sup>1</sup>H-NMR(DMSO-d<sub>6</sub>): δ 1.40(d, 3H), 2.18(s, 3H), 2.50(s, 3H),  
2.88(bd, 2H), 3.42(bd, 1H), 4.42(bd, 1H), 5.62(bd, 1H),  
7.18(m, 4H), 7.30(t, 2H), 7.63(q, 2H), 9.70(s, 1H),  
25 12.30(bd, 1H).

Example 71: Synthesis of 5,6-dimethyl-4-(N-methylphenyl-  
amino)-2-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)-  
pyrimidine hydrochloride

30

After N-methylaniline(0.6ml, 5mmol) was added to a mixture solution of 5,6-dimethyl-2-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)-4-chloropyrimidine(0.7g, 2.4mmol) and dimethylformamide(10ml), 0.45g of the titled compound was obtained in accordance with the same procedure as in Step 4 of Example 57.

Yield: 47%

- 62 -

M.P.: 91-95°C

<sup>1</sup>H-NMR(CDCl<sub>3</sub>): δ 1.32(s, 3H), 1.64(d, 3H), 1.90(bd, 1H),  
2.72(s, 3H), 3.02(bd, 1H), 3.25(bd, 1H), 3.56(s, 3H),  
3.70(bd, 1H), 5.05(bs, 1H), 5.78(bs, 1H), 7.20(m, 6H),  
5 7.42(m, 3H), 13.44(s, 1H).

Example 72: Synthesis of (R)-5,6-dimethyl-4-(N-methylphenyl-  
amino)-2-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)-  
pyrimidine hydrochloride

10

After N-methylaniline(0.6ml, 5mmol) was added to a mixture solution of (R)-5,6-dimethyl-2-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)-2-chloropyrimidine(0.7g, 2.4mmol) prepared in the Step 2 of Example 61 and dimethylformamide(10ml), 0.50g of the titled compound was obtained in accordance with the same procedure as in Step 4 of Example 57.

Yield: 52.7%

M.P.: 90-93°C

20 <sup>1</sup>H-NMR(CDCl<sub>3</sub>): δ 1.32(s, 3H), 1.64(d, 3H), 1.90(bd, 1H),  
2.72(s, 3H), 3.02(bd, 1H), 3.25(bd, 1H), 3.56(s, 3H),  
3.70(bd, 1H), 5.05(bs, 1H), 5.78(bs, 1H), 7.20(m, 6H),  
7.42(m, 3H), 13.44(s, 1H).

25 Example 73: Synthesis of (S)-5,6-dimethyl-4-(N-methyl-  
phenylamino)-2-(1-methyl-1,2,3,4-tetrahydroisoquinolin-  
2-yl)pyrimidine hydrochloride

After N-methylaniline(0.6ml, 5mmol) was added to a mixture solution of (S)-5,6-dimethyl-2-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)-4-chloropyrimidine(0.7g, 2.4mmol) prepared in the Step 2 of Example 62 and dimethylformamide(10ml), 0.42g of the titled compound was obtained in accordance with the same procedure as in Step 4 of Example 57.

Yield: 44.4%

M.P.: 91-94°C

- 63 -

<sup>1</sup>H-NMR(CDCl<sub>3</sub>): δ 1.32(s, 3H), 1.64(d, 3H), 1.90(bd, 1H), 2.72(s, 3H), 3.02(bd, 1H), 3.25(bd, 1H), 3.56(s, 3H), 3.70(bd, 1H), 5.05(bs, 1H), 5.78(bs, 1H), 7.20(m, 6H), 7.42(m, 3H), 13.44(s, 1H).

5

Example 74: Synthesis of 5,6-dimethyl-4-(2-methyl-4-fluoro-phenylamino)-2-(1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride

10 Step 1: 5,6-Dimethyl-2-(1,2,3,4-tetrahydroisoquinolin-2-yl)-4-hydroxypyrimidine

In accordance with the same procedure as in Step 2 of Example 57, except that 5,6-dimethyl-2-chloro-4-hydroxypyrimidine (6.0g, 37.8mmol) prepared in the Step 2 of Example 65 and 1,2,3,4-tetrahydroisoquinoline(10ml, 79.9mmol) were used as starting materials, 7.8g of the titled compound was prepared. (Yield: 81%)

20 Step 2: 5,6-Dimethyl-2-(1,2,3,4-tetrahydroisoquinolin-2-yl)-4-chloropyrimidine

In accordance with the same procedure as in Step 3 of Example 57, except that 5,6-dimethyl-2-(1,2,3,4-tetrahydroisoquinolin-2-yl)-4-hydroxypyrimidine(7.0g, 26mmol) prepared in the above Step 1 was used as starting materials, 4.1g of the titled compound was prepared. (Yield: 57.6%)

30 Step 3: 5,6-Dimethyl-4-(2-methyl-4-fluorophenylamino)-2-(1,2,3,4-tetrahydroisoquinoline-2-yl)pyrimidine hydrochloride

After 2-methyl-4-fluoroaniline(0.3ml, 2.7mmol) was added to a mixture solution of (5,6-dimethyl-2-(1,2,3,4-tetrahydroisoquinolin-2-yl)-4-chloropyrimidine(0.30g, 1.0mmol) and dimethylformamide(10ml), 0.12g of the titled compound was obtained in accordance with the same procedure

- 64 -

as in Step 4 of Example 57.

Yield: 30%

M.P.: 117-120°C

5  $^1\text{H-NMR(DMSO-d}_6\text{)}: \delta$  2.13(s, 3H), 2.16(s, 3H), 2.52(s, 3H),  
2.81(t, 2H), 3.79(t, 2H), 4.74(s, 2H), 7.00(bd, 1H),  
7.09-7.34(m, 6H), 9.16(s, 1H), 12.35(s, 1H).

Example 75: Synthesis of 5,6-dimethyl-4-(4-fluorophenyl-amino)-2-(1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride

10 After 4-fluoroaniline(0.24ml, 2.5mmol) was added to a mixture solution of 5,6-dimethyl-2-(1,2,3,4-tetrahydroisoquinolin-2-yl)-4-chloropyrimidine(0.33g, 1.2mmol) and 15 dimethylformamide(10ml), 0.31g of the titled compound was obtained in accordance with the same procedure as in Step 4 of Example 57.

Yield: 67%

M.P.: 128-130°C

20  $^1\text{H-NMR(DMSO-d}_6\text{)}: \delta$  2.13(s, 3H), 2.53(s, 3H), 2.90(t, 2H), 3.93(t, 2H), 4.86(s, 2H), 7.18-7.34(m, 6H), 7.63(m, 2H), 9.71(s, 1H), 12.20(bd, 1H).

Example 76: Synthesis of 5,6-dimethyl-4-(N-methylphenyl-amino)-2-(1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride

30 After N-methylaniline(0.5ml, 4.2mmol) was added to a mixture solution of 5,6-dimethyl-2-(1,2,3,4-tetrahydroisoquinolin-2-yl)-4-chloropyrimidine(0.6g, 2.0mmol) and dimethylformamide(10ml), 0.28g of the titled compound was obtained in accordance with the same procedure as in Step 4 of Example 57.

Yield: 37%

35 M.P.: 209-211°C

$^1\text{H-NMR(DMSO-d}_6\text{)}: \delta$  1.24(s, 3H), 2.41(s, 3H), 2.98(t, 2H), 3.52(s, 3H), 4.07(t, 2H), 5.02(s, 2H), 7.24-7.45(m, 9H),

12.65(bd, 1H).

Example 77: Synthesis of 5,6-dimethyl-4-(2-methyl-4-fluoro-phenylamino)-2-(7-methyl-4,5,6,7-tetrahydrothieno[2,3-c]-

5 pyridin-6-yl)pyrimidine hydrochloride

Step 1: 5,6-Dimethyl-4-(7-methyl-4,5,6,7-tetrahydrothieno-[2,3-c]pyridin-6-yl)-2-hydroxypyrimidine

10 In accordance with the same procedure as in Step 2 of Example 57, except that 5,6-dimethyl-2-chloro-4-hydroxypyrimidine(6.0g, 37.8mmol) prepared in the Step 2 of Example 65 and 7-methyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridine (12.2g, 79.6mmol) prepared in Preparation 1 were used as 15 starting materials, 6.5g of the titled compound was obtained. (Yield: 62.4%)

Step 2: 5,6-Dimethyl-4-(7-methyl-4,5,6,7-tetrahydrothieno-[2,3-c]pyridin-6-yl)-2-chloropyrimidine

20 In accordance with the same procedure as in Step 3 of Example 57, except that 5,6-dimethyl-2-(7-methyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridin-6-yl)-4-hydroxypyrimidine (6.0g, 21.8mmol) prepared in the above Step 1 was used as a 25 starting material, 3.5g of the titled compound was prepared. (Yield: 54.6%)

Step 3: 5,6-Dimethyl-4-(2-methyl-4-fluorophenylamino)-2-(7-methyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridin-6-yl)

30 pyrimidine hydrochloride

After 2-methyl-4-fluoroaniline(0.3ml, 3mmol) was added to a mixture solution of 5,6-dimethyl-2-(7-methyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridin-6-yl)-4-chloropyrimidine (0.4g, 1.4mmol) and dimethylformamide(10ml), 0.14g of the titled compound was obtained in accordance with the same procedure as in Step 4 of Example 57.

- 66 -

Yield: 24%

M.P.: 134-137°C

<sup>1</sup>H-NMR(DMSO-d<sub>6</sub>): δ 1.35(d, 3H), 2.14(s, 3H), 2.18(s, 3H),  
2.42(s, 3H), 2.65(bd, 2H), 3.56(bd, 1H), 4.54(m, 1H),  
5 5.56(bd, 1H), 6.84(d, 1H), 7.15-7.38(m, 3H), 7.41(d, 1H),  
9.72(s, 1H), 12.44(bd, 1H).

Example 78: Synthesis of 5,6-dimethyl-2-(7-methyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridin-6-yl)-4-(4-fluorophenyl-amino)pyrimidine hydrochloride

After 4-fluoroaniline(0.3ml, 3mmol) was added to a mixture solution of 5,6-dimethyl-2-(7-methyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridin-6-yl)-4-chloropyrimidine (0.4g, 1.4mmol) and dimethylformamide(10ml), 0.15g of the titled compound was obtained in accordance with the same procedure as in Step 4 of Example 57.

Yield: 26.5%

M.P.: 141-145°C

<sup>1</sup>H-NMR(DMSO-d<sub>6</sub>): δ 1.42(d, 3H), 2.16(s, 3H), 2.52(s, 3H),  
2.70(bd, 2H), 3.38(m, 1H), 4.65(bd, 1H), 5.75(bd, 1H),  
6.84(d, 1H), 7.30(m, 2H), 7.42(d, 1H), 7.61(m, 2H), 9.80(s, 1H), 12.62(bd, 1H).

Example 79: Synthesis of 5,6-dimethyl-4-(N-methylphenyl-amino)-2-(7-methyl-4,5,6,7-tetrahydrothieno[2,3-c]-pyridin-6-yl)pyrimidine hydrochloride

After N-methylaniline(0.5ml, 4mmol) was added to a mixture solution of 5,6-dimethyl-2-(7-methyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridin-6-yl)-4-chloropyrimidine(0.64g, 2mmol) and dimethylformamide(10ml), 0.16g of the titled compound was obtained in accordance with the same procedure as in Step 4 of Example 57.

Yield: 20%

M.P.: 117-120°C

<sup>1</sup>H-NMR(CDCl<sub>3</sub>): δ 1.32(s, 3H), 1.65(d, 3H), 2.72(s, 3H),

- 67 -

2.78(bd, 1H), 3.20(bd, 1H), 3.51(bd, 1H), 3.56(s, 3H), 5.36(bd, 1H), 6.03(bd, 1H), 6.82(d, 1H), 6.88(m, 3H), 7.37-7.48(m, 3H), 14.52(s, 1H).

5 Example 80: Synthesis of 5-methyl-6-ethyl-4-(2-methyl-4-fluorophenylamino)-2-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride

Step 1: 5-Methyl-6-ethyl-2-chloro-4-hydroxypyrimidine

10 In accordance with the same procedure as in Step 1 of Example 57, except that 2,4-dichloro-5-methyl-6-ethyl pyrimidine(2.7g, 14.1mmol) prepared in Preparation 4 was used as a starting material, 1.8g of the titled compound was prepared. (Yield: 72%)

15

Step 2: 5-Methyl-6-ethyl-2-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)-4-hydroxypyrimidine

20 In accordance with the same procedure as in Step 2 of Example 57, except that 5-methyl-6-ethyl-2-chloro-4-hydroxypyrimidine(1.8g, 10.1mmol) prepared in the above Step 1 was used as a starting material, 2.4g of the titled compound was prepared. (Yield: 84%)

25 Step 3: 5-Methyl-6-ethyl-2-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)-4-chloropyrimidine

30 In accordance with the same procedure as in Step 3 of Example 57, except that 5-methyl-6-ethyl-2-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)-4-hydroxypyrimidine(2.4g, 8.5mmol) prepared in the above Step 2 was used as a starting material, 1.6g of the titled compound was prepared. (Yield: 62.4%)

35 Step 4: 5-Methyl-6-ethyl-4-(2-methyl-4-fluorophenylamino)-2-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)-pyrimidine hydrochloride

- 68 -

After 2-methyl-4-fluoroaniline(0.42ml, 3.8mmol) was added to a mixture solution of 5-methyl-6-ethyl-2-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)-4-chloropyrimidine(0.6g, 2.0mmol) and dimethylformamide(10ml), 0.35g of the titled compound was obtained in accordance with the same procedure as in Step 4 of Example 57.

5 Yield: 41%

M.P.: 270-272°C

10  $^1\text{H-NMR}(\text{DMSO-d}_6)$ :  $\delta$  1.22(t, 3H), 1.35(d, 3H), 2.16(s, 3H), 2.20(s, 3H), 2.75-3.00(m, 4H), 3.48(m, 1H), 4.20(m, 1H), 5.38(bs, 1H), 7.00-7.40(m, 7H).

15 Example 81: Synthesis of 4-(2-methyl-4-fluorophenylamino)-2-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)cyclopenta[d]pyrimidine hydrochloride

Step 1: 2-chloro-4-hydroxycyclopenta[d]pyrimidine

20 In accordance with the same procedure as in Step 1 of Example 57, except that 2,4-dichlorocyclopenta[d]pyrimidine (2.7g, 14.3mmol) prepared in Step 3 of Example 29 was used as a starting material, 1.7g of the title compound was prepared. (Yield: 69.7%)

25 Step 2: 2-(1-Methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)-2-hydroxycyclopenta[d]pyrimidine

30 In accordance with the same procedure as in Step 2 of Example 57, except that 2-chloro-4-hydroxycyclopenta[d]-pyrimidine(1.7g, 10.0mmol) prepared in the above Step 1 was used as a starting material, 2.2g of the titled compound was prepared. (Yield: 78.2%)

35 Step 3: 2-(1-Methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)-4-chlorocyclopenta[d]pyrimidine

In accordance with the same procedure as in Step 3 of

- 69 -

Example 57, except that 2-(1-methyl-1,2,3,4-tetrahydroisoquinoline-2-yl)-2-hydroxycyclopenta[d]pyrimidine(2.2g, 7.8mmol) prepared in the above Step 2 was used as a starting material, 1.5g of the titled compound was prepared.

5 (Yield: 64%)

**Step 4: 4-(2-Methyl-4-fluorophenylamino)-2-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)cyclopenta[d]pyrimidine hydrochloride**

10

After 2-methyl-4-fluoroaniline(0.46ml, 4.2mmol) was added to a mixture solution of 2-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)-4-chlorocyclopenta[d]pyrimidine(0.6g, 2.0mmol) and dimethylformamide(10ml), 0.10g of the titled compound was obtained in accordance with the same procedure as in Step 4 of Example 57.

Yield: 12%

M.P.: 165-168°C

<sup>1</sup>H-NMR(CDCl<sub>3</sub>): δ 1.40(m, 2H), 1.62(d, 3H), 2.22(m, 2H), 2.30(s, 3H), 2.62-2.98(bd, 3H), 3.30(m, 2H), 3.70(bd, 1H), 4.73(bs, 1H), 5.32(bs, 1H), 6.98(m, 2H), 7.20(m, 5H), 14.02(bd, 1H).

**Example 82: Synthesis of 2-(2-methyl-4-fluorophenylamino)-4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)-5,6,7,8-tetrahydroquinazoline hydrochloride**

**Step 1: 2-chloro-4-hydroxy-5,6,7,8-tetrahydroquinazoline**

30 In accordance with the same procedure as in Step 1 of Example 57, except that 2,4-dichloro-5,6,7,8-tetrahydroquinazoline(6.4g, 31.6mmol) prepared in the Step 2 of Example 32 was used as a starting material, 4.2g of the titled compound was prepared. (Yield: 72%)

35

**Step 2: 2-(1-Methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)-4-hydroxy-5,6,7,8-tetrahydroquinazoline**

- 70 -

In accordance with the same procedure as in Step 2 of Example 57, except that 2-chloro-4-hydroxy-5,6,7,8-tetrahydroquinazoline (2.0g, 10.8mmol) prepared in the above Step 1 and 1-methyl-1,2,3,4-tetrahydroisoquinoline(3.3g, 5 22.4mmol) were used as starting materials, 1.1g of the titled compound was prepared. (Yield: 34.5%)

**Step 3: 2-(1-Methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)-4-chloro-5,6,7,8-tetrahydroquinazoline**

10 In accordance with the same procedure as in Step 3 of Example 57, except that 2-(1-methyl-1,2,3,4-tetrahydroisoquinoline-2-yl)-4-hydroxy-5,6,7,8-tetrahydroquinazoline (1.1g, 3.7mmol) prepared in the above Step 2 was used as a 15 starting material, 0.7g of the titled compound was prepared. (Yield: 60.3%)

**Step 4: 4-(2-Methyl-4-fluorophenylamino)-2-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)-5,6,7,8-tetrahydro-20 quinazoline hydrochloride**

After 4-fluoro-2-methylaniline(0.3ml, 2.7mmol) was added to a mixture solution of 2-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)-4-chloro-5,6,7,8-tetrahydroquinazoline(0.35g, 1.1mmol) and dimethylformamide(5ml), 0.15g of the titled compound was obtained in accordance with the same procedure as in Step 4 of Example 57.

Yield: 31%

M.P.: 181-184°C

30  $^1\text{H-NMR}(\text{DMSO-d}_6)$ :  $\delta$  1.32(d, 3H), 1.80(bd, 4H), 2.18(s, 3H), 2.85(bd, 4H), 3.40(bd, 1H), 3.65(bd, 2H), 4.25(m, 1H), 5.40(bd, 1H), 7.05-7.38(m, 7H), 9.62(s, 1H), 12.20(s, 1H).

**Example 83: Synthesis of 4-(2-methyl-4-fluorophenylamino)-2-(1,2,3,4-tetrahydroisoquinolin-2-yl)-5,6,7,8-tetrahydro-35 quinazoline hydrochloride**

- 71 -

Step 1: 2-(1,2,3,4-tetrahydroisoquinolin-2-yl)-4-hydroxy-5,6,7,8-tetrahydroquinazoline

In accordance with the same procedure as in Step 2 of Example 57, except that 2-chloro-4-hydroxy-5,6,7,8-tetrahydroquinazoline (2.0g, 10.8mmol) prepared in Step 1 of Example 82 and 1,2,3,4-tetrahydroisoquinoline (2.8g, 22.4mmol) were used as starting materials, 0.8g of the titled compound was prepared. (Yield: 26.3%)

10

Step 2: 2-(1,2,3,4-tetrahydroisoquinolin-2-yl)-4-chloro-5,6,7,8-tetrahydroquinazoline

In accordance with the same procedure as in Step 3 of Example 57, except that 2-(1,2,3,4-tetrahydroisoquinolin-2-yl)-4-hydroxy-5,6,7,8-tetrahydroquinazoline(0.8g, 2.8mmol) prepared in the above Step 1 was used as a starting material, 0.6g of the titled compound was prepared. (Yield: 71.5%)

20

Step 3: 4-(2-Methyl-4-fluorophenylamino)-2-(1,2,3,4-tetrahydroisoquinolin-2-yl)-5,6,7,8-tetrahydroquinazoline hydrochloride

25 After 4-fluoro-2-methylaniline(0.3ml, 2.7mmol) was added to a mixture solution of 2-(1,2,3,4-tetrahydroisoquinolin-2-yl)-4-chloro-5,6,7,8-tetrahydroquinazoline(0.3g, 1.0mmol) and dimethylformamide(5ml), 0.2g of the titled compound was prepared in accordance with the same procedure  
30 as in Step 4 of Example 57.

Yield: 47.1%

M.P.: 150-152°C

$^1\text{H-NMR(DMSO-d}_6\text{)}$ :  $\delta$  1.76(bd, 4H), 2.15(s, 3H), 2.81(bd, 4H), 3.46(bd, 2H), 3.77(bd, 2H), 4.74(s, 1H), 7.02-7.33(m, 7H),

35 9.59(s, 1H), 12.40(bd, 1H).

- 72 -

Test 1: Inhibition of proton pump( $H^+/K^+$  ATPase) activity

A proton pump enzyme source was prepared by the same method as in Experiment 1-1 of WO 94/14795. Further, the 5 inhibitory effect of proton pump activity was measured by the same method as in Experiment 1-2 of WO 94/14795.

Namely, the proton pump activity stimulated by  $Mg^{++}$  was used as a negative comparative group, and the activity stimulated by  $Mg^{++}$  and  $K^+$  was used as a positive comparative 10 group. The comparative compound was omeprazole.

Test tubes were divided into 4 groups: Group 1 as negative comparative group( $n=3$ ), Group 2 as positive comparative group( $n=3$ ), Group 3( $n=5 \times 2$ ) to be administered with the compound of the present invention and Group 15 4( $n=5 \times 2$ ) to be administered with the comparative compound.

The inhibitory effects of Groups 3 and 4 on proton pump activity were measured by employing the compound prepared in Example and omeperazole, respectively, each of which was dissolved in dimethylsulfoxide at 5 different 20 concentrations.

To each of Groups 1, 2, 3 and 4 were added  $100\mu l$  of magnesium chloride( $40mM$ ) dissolved in  $40mM$  Tris-HCl buffer( $pH 6.0$ ) and  $100\mu l$  of the enzyme source. Then,  $50\mu l$  of potassium chloride( $50mM$ ) and  $50\mu l$  of ammonium chloride( $6mM$ ) 25 dissolved in  $40mM$  Tris-HCl buffer( $pH 6.0$ ) were added to all groups except for Group 1.

$10\mu l$  of dimethylsulfoxide was added to each of Groups 1 and 2; and to Group 3 was added  $10\mu l$  of the solution in which the compound prepared in Example was dissolved in 30 dimethylsulfoxide at 5 different concentrations( $n=5 \times 2$ ). To Group 4,  $10\mu l$  of the solution prepared by dissolving omeprazole in dimethylsulfoxide at 5 different concentrations( $37.6$ ,  $21.4$ ,  $12.2$ ,  $7.0$  and  $4.0\mu M$ ) was added( $n=5 \times 2$ ).  $40mM$  Tris-HCl buffer( $pH=6.0$ ) was added thereto 35 so as to make the total volume  $400\mu l$ .

Thereafter, the test tubes of each Group were placed at  $37^\circ C$  for 30 minutes for the preincubation.  $100\mu l$  of ATP

solution (6.6mM) was added until the reaction volume became 500 $\mu$ l. After the reaction was carried out at 37°C for 30 minutes, 25% cold trichloroacetic acid was added to terminate the enzyme reaction. The released inorganic phosphate was measured by an automatic analyzer(Express 550, Corning).

The difference between Group 1 and Group 2 represents the proton pump activity activated by K<sup>+</sup> only. The inhibition percentages of Groups 3 and 4 were calculated from Litchfield-wilcoxon equation[see, e.g., J. pharmacol. Exp. Ther., 96, 99(1949)]. The concentrations of the test compounds which inhibit 50% of the proton pump activity are represented as IC50 in Table 1.

15

Table 1

20	Test compound	IC50( $\mu$ M)		Effect ratio
		Test compound	Omeprazole	
25	Example 1	5.4	5.8	1.08
	Example 2	0.9	7.3	7.82
	Example 3	3.5	7.3	2.11
	Example 5	1.3	6.4	4.91
	Example 6	4.3	6.4	4.91
30	Example 8	~12.5	7.7	~0.60
	Example 9	~10.0	11.2	~1.12
	Example 10	10.6	7.3	0.69
	Example 12	0.6	5.8	9.83
	Example 13	0.5	5.8	10.70
35	Example 14	0.7	5.8	8.70
	Example 15	1.6	5.8	3.69
	Example 16	1.5	5.8	3.80
	Example 17	1.8	5.8	3.20
	Example 18	4.2	11.4	2.69

- 74 -

Table 1 (continued)

5	Test compound	IC50 (μM)		Effect ratio
		Test compound	Omeprazole	
10	Example 19	3.9	11.4	2.92
	Example 20	4.4	11.4	2.59
	Example 21	1.5	10.9	7.33
	Example 22	1.4	10.9	7.26
	Example 23	2.0	10.9	5.45
15	Example 24	0.6	10.9	19.33
	Example 25	1.4	11.1	8.10
	Example 26	0.8	12.6	15.62
	Example 27	2.1	12.9	6.26
	Example 28	>15.0	14.2	<0.95
20	Example 29	0.4	6.4	17.49
	Example 30	~8.4	14.2	~1.69
	Example 31	~15.0	7.1	~0.51
	Example 32	1.2	10.1	8.40
	Example 34	1.0	10.1	4.02
25	Example 35	2.5	10.1	4.02
	Example 37	0.7	7.1	9.85
	Example 38	2.2	7.1	3.24
	Example 39	>15.0	14.2	<0.95
	Example 40	0.7	6.4	9.17
30	Example 41	0.6	10.1	18.10
	Example 42	1.5	7.3	4.95
	Example 43	0.5	7.1	14.44
	Example 44	~11.3	12.2	~1.08
	Example 45	3.1	12.90	4.12
35	Example 46	~19.2	12.20	~0.60
	Example 47	~5.0	7.70	~1.54
	Example 48	~5.5	10.80	~1.97
	Example 49	~10.8	12.20	~1.13
	Example 50	~16.9	12.20	~0.70
40	Example 51	1.1	8.00	7.05
	Example 52	0.5	11.40	21.11
	Example 53	2.1	11.40	5.38
	Example 54	20.6	10.10	0.49
	Example 55	2.1	10.10	4.80
45				
50				
55				

- 75 -

Table 1 (continued)

5	Test compound	IC50 (μM)		Effect ratio
		Test compound	Omeprazole	
10	Example 57	3.3	11.5	3.50
	Example 58	>25.0	11.3	<0.45
	Example 59	~12.5	7.7	~0.60
	Example 60	~15.0	7.7	~0.51
	Example 61	~12.5	7.7	~0.60
15	Example 62	>20.0	14.2	<0.71
	Example 63	~12.0	14.2	~1.18
	Example 64	~10.0	14.2	~1.42
	Example 65	1.0	5.8	6.04
	Example 66	0.9	5.8	6.40
20	Example 67	1.3	5.8	4.50
	Example 68	3.1	5.8	1.86
	Example 69	2.9	5.8	2.00
	Example 70	3.5	5.8	1.70
	Example 74	0.5	10.1	22.00
25	Example 75	1.2	7.1	5.89
	Example 77	3.6	11.4	3.16
	Example 78	8.5	11.4	1.35
	Example 81	0.4	6.4	15.82
	Example 82	1.1	10.1	9.40
30	Example 83	1.4	7.3	5.34

- 76 -

Test 2: Inhibition of gastric secretion

In accordance with the method disclosed in journal [Shay, H., et al., Gastroenterology, 5, 43-61(1945), 5 inhibitory effect on gastric secretion was carried out.

Male Sprague-Dawley rats having a body weight of  $200 \pm 10$ g were divided into 3 groups(n=5) and fasted for 24 hours before the experiment with free access to water. Under ether anesthesia, the abdomen was incised, and the pylorus 10 was ligated. As a comparative group, Group 1 was administered intraduodenally in a volume of 0.5mg/200g of 30% aqueous polyethylene glycol 400 solution. Groups 2 and 15 3 were administered intraduodenally with the compound of Example and omeprazole, respectively, each of which was suspended in 30% aqueous polyethylene glycol 400 solution at a concentration of 20mg/kg. After closing the abdominal cavity, the rats were placed for 5 hours and then killed by cervical dislocation. The stomach was extracted to obtain 20 gastric juice.

25 The gastric juice was centrifuged at 1,000g to remove precipitates. The amount and acidity of the gastric juice were measured. Relative volumes, relative acid concentrations and relative acid outputs of the test compounds were calculated from equations(I), (II) and (III) and the results are shown in Table 2.

Relative volume ..... (I)

= (the average amount of gastric juice of Group 1 -  
the average amount of gastric juice of Group 2)

30 / (the average amount of gastric juice of group 1-  
the average amount of gastric juice of Group 3)

Relative acid concentration..... (II)

= (the average acidity of Group 1 - the average acidity  
35 of Group 2)  
/ (the average acidity of Group 1- the average acidity  
of Group 3)

- 77 -

Relative acid output ..... (III)

= (the total amount of acid output of Group 1- the total amount of acid output of Group 2)

5 / (the total amount of acid output of Group 1- the total amount of acid output of Group 3).

Table 2

	Compound	Rel. Vol. (%)	Rel. Conc. (%)	Relative Acid Output
15	Example 1	0.12	0.00	0.11
	Example 2	0.92	0.8	0.89
	Example 3	0.76	0.81	0.87
	Example 4	0.99	0.56	0.87
	Example 5	0.59	0.27	0.61
	Example 6	0.64	0.28	0.64
	Example 7	0.51	0.09	0.48
	Example 8	0.43	0.12	0.42
	Example 9	0.4	-0.03	0.3
	Example 10	0.58	0.47	0.55
25	Example 11	0.99	0.41	0.82
	Example 12	1.64	0.29	0.75
	Example 13	1.72	0.46	0.81
	Example 14	0.53	0.3	0.72
	Example 15	0.8	1.06	0.99
	Example 16	0.96	1.24	1.13
	Example 17	0.82	0.97	0.89
	Example 18	1.72	1.82	1.39
	Example 19	1.8	1.86	1.43
	Example 20	1.66	1.75	1.28
40	Example 21	1.06	0.88	0.97
	Example 22	0.99	0.80	0.90
	Example 23	0.92	0.78	0.88
	Example 24	1.00	1.03	1.01
	Example 25	1.06	0.80	0.92
	Example 26	0.6	0.53	0.73
	Example 27	0.7	0.61	0.81
	Example 28	0.71	0.44	0.78
	Example 29	0.56	0.31	0.6
	Example 30	0.33	0.2	0.39

- 78 -

Table 2 (continued)

	Compound	Rel. Vol. (%)	Rel. Conc. (%)	Relative Acid Output
5	Example 31	0.83	0.21	0.74
	Example 32	1.03	0.97	0.91
10	Example 33	0.93	1.13	0.94
	Example 34	0.99	1	0.99
	Example 35	1.05	0.84	0.94
	Example 36	0.65	0.05	0.41
15	Example 37	0.82	0.42	0.82
	Example 38	0.74	0.37	0.74
	Example 39	0.58	0.18	0.56
	Example 40	0.71	0.36	0.74
20	Example 41	0.94	1.87	1.12
	Example 42	1.15	1.4	1.15
	Example 43	0.7	0.59	0.82
	Example 44	0.27	0.33	0.41
25	Example 45	0.84	0.75	0.89
	Example 46	0.73	0.44	0.74
	Example 47	0.38	0.14	0.38
	Example 48	0.17	0.04	0.16
	Example 49	0.2	0.02	0.16
	Example 50	0.72	0.29	0.66
30	Example 51	0.59	0.12	0.59
	Example 52	1.34	0.94	1.12
	Example 53	0.47	1.14	0.55
35	Example 54	0.86	0.23	0.75
	Example 55	0.56	0.11	0.51
	Example 56	0.01	0.08	0.08
	Example 57	1.20	0.27	0.61
40	Example 58	0.58	0.16	0.35
	Example 59	0.51	0.25	0.56
	Example 60	0.65	0.28	0.65
45	Example 61	0.32	0.22	0.40
	Example 62	0.61	0.31	0.67
	Example 63	0.69	0.33	0.72
	Example 64	0.34	0.26	0.40
	Example 65	1.43	0.35	0.71
50	Example 66	1.49	0.47	0.85
	Example 67	1.36	0.31	0.62
	Example 68	1.52	0.23	0.67
	Example 69	1.61	0.39	0.76
	Example 70	1.30	0.22	0.61

Table 2 (continued)

	Compound	Rel. Vol. (%)	Rel. Conc. (%)	Relative Acid Output
5	Example 71	0.25	-0.07	0.16
	Example 72	0.34	0.16	0.25
	Example 73	0.18	-0.05	0.13
	Example 74	1.22	1.49	1.16
	Example 75	1.30	1.62	1.20
	Example 76	0.28	0.17	0.33
	Example 77	1.48	1.63	1.30
	Example 78	1.06	1.75	1.09
	Example 79	0.54	1.28	0.49
	Example 80	0.32	0.29	0.44
20	Example 81	0.56	0.47	0.68
	Example 82	0.69	0.59	0.79
	Example 83	1.19	1.29	1.13

25

## Test 3. Reversibility Test

30      Gastric vesicles were prepared by the same method as in Experiment 4-1 of WO 94/14795. The inhibition mechanism of proton pump activity by the present invention compound was tested in accordance with the so-called Dilution and Washout method [see e.g., D. J. Keeling, et al., Biochemical Pharmacology, 42(1), 123-130(1991)].

35      Namely, test tubes were divided into two group, Groups 1 and 2. Each group was divided into four subgroups. 90 $\mu$ l of 5 mM Pipes/Tris buffer(pH 7.4) and 10 $\mu$ l of DMSO were added to subgroups 1 and 2 of each group. 90 $\mu$ l of 5 mM Pipes/Tris buffer(pH 7.4) and 10 $\mu$ l of the compound prepared in Example 43(50 $\mu$ M) were added to subgroups 3 and 4 of each group. To all two groups, was added 100 $\mu$ l of lyophilized vesicles at the concentration of 100 $\mu$ g protein/ml and then preincubated at 37°C for 15 minutes.

40      2mM MgCl<sub>2</sub> was added to subgroups 1 and 3 of Group 1. 2mM MgCl<sub>2</sub> and 10mM KCl were added to subgroups 2 and 4 of

- 80 -

Group 1. 3mM ATP was added to all subgroups of Group 1 until the final volume became 500 $\mu$ l. After incubation for 30 minutes, the inhibition of H<sup>+</sup>/K<sup>+</sup>-ATPase activity by the test compound was measured.

5 After preincubation as described above, each subgroup of Group 2 was diluted with 50-fold volume of 5 mM Pipes/Tris buffer(pH7.4) and then centrifuged for 60 minutes by means of Beckman ultracentrifuge(Model L8-80). The supernatant was discarded and washed out by 10 ml of 5 mM  
10 Pipes/Tris buffer(pH 7.4). The resulting pellet was suspended with 5mM Pipes/Tris buffer (pH7.4) until the volume became the same as the preincubation volume.

Thereafter, in accordance with the treatment to Group 1, each subgroup of Group 2 was treated with 2mM MgCl<sub>2</sub>, 10mM  
15 KCl and 3mM ATP. And the final volume of each subgroup of Group 2 was made to be 500 $\mu$ l. After incubation at 37°C for 30 minutes, the inhibition of H<sup>+</sup>/K<sup>+</sup>-ATPase activity was measured.

20 And it was further measured in accordance with the same procedures as above, except the compound prepared in Example 75 was used as a test compound. The inhibition of H<sup>+</sup>/K<sup>+</sup> ATPase activity before and after the Dilution and Washout procedures is shown in Table 3.

25

Table 3

30	Compound	<u>Dilution &amp; Washout</u>	
		Before	After
	Example 43	62	6
35	Example 75	66.6	15

As shown in Table 3, the compounds of Examples 43 and 75 inhibit the enzyme activity by 62% and 66.6% before the  
40 Dilution and Washout procedure, whereas they show 6 or 15%

- 81 -

of inhibition of the enzyme activity after the Dilution and Washout procedure. This indicates that the inhibition of the enzyme activity of the present invention compounds is reversible.



5 While the invention has been described with respect to the specific embodiments, it should be recognized that various modifications and changes may be made by those skilled in the art to the invention which also fall within the scope of the invention as defined as the appended  
10 claims.

- 82 -

What is claimed is :

1. Pyrimidine derivative compounds of formulae (I-1) and (I-2) inclusive of pharmaceutically acceptable salts  
 5 thereof:


10



wherein:

15  $R_4$  and  $R_5$ , which may be the same or different, are independently hydrogen or a  $C_1$ - $C_3$  alkyl group, or jointly form a cyclopentyl or cyclohexyl ring;  
 A is a group of formula(II):


20




wherein  $R_1$  and  $R_2$  are, independently of each other, hydrogen or a  $C_1$ - $C_3$  alkyl group, and  $R_3$  is hydrogen, a  $C_1$ - $C_3$  alkyl group or a halogen; and

25 B is 1-(substituted)-1,2,3,4-tetrahydroisoquinolin-2-yl of formula (III-1) or 7-(substituted)-4,5,6,7-tetrahydro-thieno[2,3-c]pyridin-6-yl of formula (III-2)

30



(III-1)



(III-2)

35

wherein  $R_6$  is hydrogen or a  $C_1$ - $C_3$  alkyl group.

2. The compound of claim 1, which is selected from the group consisting of:

2-(2-methyl-4-fluorophenylamino)-4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride;

5 6-methyl-2-(2-methyl-4-fluorophenylamino)-4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride;

6-methyl-4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)-2-(4-fluorophenylamino)pyrimidine hydrochloride;

10 6-methyl-2-(N-methylphenylamino)-4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride;

6-ethyl-2-(2-methyl-4-fluorophenylamino)-4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride;

15 6-ethyl-2-(4-fluorophenylamino)-4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride;

6-ethyl-2-(N-methylphenylamino)-4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride;

20 6-ethyl-2-(2-methylphenylamino)-4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)-6-propylpyrimidine hydrochloride;

4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)-6-propyl-2-(4-fluorophenylamino)pyrimidine hydrochloride;

2-(N-methylphenylamino)-4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)-6-propylpyrimidine hydrochloride;

25 5,6-dimethyl-2-(2-methyl-4-fluorophenylamino)-4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride;

(R)-5,6-dimethyl-2-(2-methyl-4-fluorophenylamino)-4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride;

30 (S)-5,6-dimethyl-2-(2-methyl-4-fluorophenylamino)-4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride;

5,6-dimethyl-2-(4-fluorophenylamino)-4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride;

35 (R)-5,6-dimethyl-2-(4-fluorophenylamino)-4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride;

(S)-5,6-dimethyl-2-(4-fluorophenylamino)-4-(1-methyl-1,2,

3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride;  
5,6-dimethyl-2-(N-methylphenylamino)-4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride;  
(R)-5,6-dimethyl-2-(N-methylphenylamino)-4-(1-methyl-1,2,  
5 3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride;  
(S)-5,6-dimethyl-2-(N-methylphenylamino)-4-(1-methyl-1,2,  
3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride;  
5,6-dimethyl-2-(phenylamino)-4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride;  
10 (R)-5,6-dimethyl-2-(4-phenylamino)-4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride;  
(S)-5,6-dimethyl-2-(4-fluorophenylamino)-4-(1-methyl-1,2,  
3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride;  
5,6-dimethyl-2-(2-methylphenylamino)-4-(1-methyl-1,2,3,4-  
15 tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride;  
5,6-dimethyl-2-(4-methylphenylamino)-4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride;  
5-methyl-6-ethyl-2-(2-methyl-4-fluorophenylamino)-4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine  
20 hydrochloride;  
5-methyl-6-ethyl-2-(4-fluorophenylamino)-4-(1-methyl-1,2,  
3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride;  
5-methyl-6-ethyl-2-(N-methylphenylamino)-4-(1-methyl-1,2,  
3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride;  
25 2-(2-methyl-4-fluorophenylamino)-4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)cyclopenta[d]pyrimidine hydrochloride;  
2-(4-fluorophenylamino)-4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)cyclopenta[d]pyrimidine hydrochloride;  
2-(N-methylphenylamino)-4-(1-methyl-1,2,3,4-tetrahydroiso-  
30 quinolin-2-yl)cyclopenta[d]pyrimidine hydrochloride;  
2-(2-methyl-4-fluorophenylamino)-4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)-5,6,7,8-tetrahydroquinazoline  
hydrochloride;  
2-(N-methylphenylamino)-4-(1-methyl-1,2,3,4-tetrahydroiso-  
35 quinoline-2-yl)-5,6,7,8-tetrahydroquinazoline hydrochloride;  
6-methyl-2-(2-methyl-4-fluorophenylamino)-4-(1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride;

6-methyl-2-(4-fluorophenylamino)-4-(1,2,3,4-tetrahydroisoquinoline-2-yl)pyrimidine hydrochloride;

6-methyl-2-(N-methylphenylamino)-4-(1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride;

5 6-ethyl-2-(2-methyl-4-fluorophenylamino)-4-(1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride;

6-ethyl-2-(4-fluorophenylamino)-4-(1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride;

6-ethyl-2-(N-methylphenylamino)-4-(1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride;

10 6-ethyl-2-(2-methylphenylamino)-4-(1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride;

5,6-dimethyl-2-(2-methyl-4-fluorophenylamino)-4-(1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride;

15 5,6-dimethyl-2-(4-fluorophenylamino)-4-(1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride;

5,6-dimethyl-2-(N-methylphenylamino)-4-(1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride;

5-methyl-6-ethyl-2-(2-methyl-4-fluorophenylamino)-4-(1,2,

20 3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride;

5-methyl-6-ethyl-2-(4-fluorophenylamino)-4-(1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride;

5-methyl-6-ethyl-2-(N-methylphenylamino)-4-(1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride;

25 2-(2-methyl-4-fluorophenylamino)-4-(1,2,3,4-tetrahydroisoquinolin-2-yl)cyclopenta[d]pyrimidine hydrochloride;

2-(2-methyl-4-fluorophenylamino)-4-(1,2,3,4-tetrahydroisoquinolin-2-yl)-5,6,7,8-tetrahydroquinazolinehydrochloride;

2-(4-fluorophenylamino)-4-(1,2,3,4-tetrahydroisoquinolin-

30 2-yl)-5,6,7,8-tetrahydroquinazoline hydrochloride;

2-(N-methylphenylamino)-4-(1,2,3,4-tetrahydroisoquinolin-2-yl)-5,6,7,8-tetrahydroquinazoline hydrochloride;

2-(2-methylphenylamino)-4-(1,2,3,4-tetrahydroisoquinolin-2-yl)-5,6,7,8-tetrahydroquinazoline hydrochloride;

35 6-methyl-2-(2-methyl-4-fluorophenylamino)-4-(7-methyl-4,5,

6,7-tetrahydrothieno[2,3-c]pyridin-6-yl)pyrimidine hydrochloride;

- 86 -

6-methyl-4-(7-methyl-4,5,6,7-tetrahydrothieno[2,3-c]-pyridin-6-yl)-2-(4-fluorophenylamino)pyrimidine hydrochloride;

6-methyl-2-(N-methylphenylamino)-4-(7-methyl-4,5,6,7-tetra-  
5 hydrothieno[2,3-c]pyridin-6-yl)pyrimidine hydrochloride;

5,6-dimethyl-2-(2-methyl-4-fluorophenylamino)-4-(7-methyl-  
10 4,5,6,7-tetrahydrothieno[2,3-c]pyridin-6-yl)pyrimidine hydrochloride;

5-methyl-2-(2-methyl-4-fluorophenylamino)-4-(7-methyl-4,5,  
15 6,7-tetrahydrothieno[2,3-c]pyridin-6-yl)-6-ethylpyrimidine hydrochloride;

6-methyl-4-(2-methyl-4-fluorophenylamino)-2-(1-methyl-1,2,  
20 3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride;

6-methyl-4-(4-fluorophenylamino)-2-(1-methyl-1,2,3,4-tetra-  
25 hydroisoquinolin-2-yl)pyrimidine hydrochloride;

6-methyl-4-(2-methyl-4-fluorophenylamino)-2-(7-methyl-4,5,  
30 6,7-tetrahydrothieno[2,3-c]pyridin-6-yl)pyrimidine hydrochloride;

6-methyl-4-(4-fluorophenylamino)-2-(7-methyl-4,5,6,7-tetra-  
35 hydrothieno[2,3-c]pyridin-6-yl)pyrimidine hydrochloride;

6-ethyl-2-(2-methyl-4-fluorophenylamino)-4-(1-methyl-1,2,  
40 3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride;

6-ethyl-4-(2-methyl-4-fluorophenylamino)-2-(1,2,3,4-tetra-  
45 hydroisoquinolin-2-yl)pyrimidine hydrochloride;

6-ethyl-4-(4-fluorophenylamino)-2-(1,2,3,4-tetrahydroiso-  
50 quinolin-2-yl)pyrimidine hydrochloride;

6-ethyl-4-(N-methylphenylamino)-2-(1,2,3,4-tetrahydroiso-  
55 quinolin-2-yl)pyrimidine hydrochloride;

5,6-dimethyl-4-(2-methyl-4-fluorophenylamino)-2-(1-methyl-  
60 1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride;

(R)-5,6-dimethyl-4-(2-methyl-4-fluorophenylamino)-2-(1-  
65 methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride;

(S)-5,6-dimethyl-4-(2-methyl-4-fluorophenylamino)-2-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride;

5,6-dimethyl-4-(4-fluorophenylamino)-2-(1-methyl-1,2,3,4-


tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride;  
(R)-5,6-dimethyl-4-(4-fluorophenylamino)-2-(1-methyl-1,2,-  
3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride;  
(S)-5,6-dimethyl-4-(4-fluorophenylamino)-2-(1-methyl-1,2,-  
5 3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride;  
5,6-dimethyl-4-(N-methylphenylamino)-2-(1-methyl-1,2,3,4-  
tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride;  
(R)-5,6-dimethyl-4-(N-methylphenylamino)-2-(1-methyl-1,2,  
3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride;  
10 (S)-5,6-dimethyl-4-(N-methylphenylamino)-2-(1-methyl-1,2,  
3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride;  
5,6-dimethyl-4-(2-methyl-4-fluorophenylamino)-2-(1,2,3,4-  
tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride;  
5,6-dimethyl-4-(4-fluorophenylamino)-2-(1,2,3,4-tetrahydro-  
15 isoquinolin-2-yl)pyrimidine hydrochloride;  
5,6-dimethyl-4-(N-methylphenylamino)-2-(1,2,3,4-tetrahydro-  
isoquinolin-2-yl)pyrimidine hydrochloride;  
5,6-dimethyl-4-(2-methyl-4-fluorophenylamino)-2-(7-methyl-  
4,5,6,7-tetrahydrothieno[2,3-c]pyridin-6-yl)pyrimidine  
20 hydrochloride;  
5,6-dimethyl-2-(7-methyl-4,5,6,7-tetrahydrothieno[2,3-c]-  
pyridin-6-yl)-4-(4-fluorophenylamino)pyrimidine  
hydrochloride;  
5,6-dimethyl-4-(N-methylphenylamino)-2-(7-methyl-4,5,6,7-  
25 tetrahydrothieno[2,3-c]pyridin-6-yl)pyrimidine  
hydrochloride;  
5-methyl-6-ethyl-4-(2-methyl-4-fluorophenylamino)-2-(1-  
methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine  
hydrochloride;  
30 4-(2-methyl-4-fluorophenylamino)-2-(1-methyl-1,2,3,4-tetra-  
hydroisoquinolin-2-yl)cyclopenta[d]pyrimidine hydrochloride;  
2-(2-methyl-4-fluorophenylamino)-4-(1-methyl-1,2,3,4-tetra-  
hydroisoquinolin-2-yl)-5,6,7,8-tetrahydroquinazoline  
hydrochloride; and  
35 4-(2-methyl-4-fluorophenylamino)-2-(1,2,3,4-tetrahydroiso-  
quinolin-2-yl)-5,6,7,8-tetrahydroquinazoline hydrochloride.

- 88 -


3. The compound of claim 1, wherein the pharmaceutically acceptable salts are hydrochlorides, sulfates, phosphates, nitrates, tartrates, fumarates, citrates, mesylates or acetates of the pyrimidine derivative 5 compounds of formulae (I-1) and (I-2).

4. A process for preparing a pyrimidine derivative compound of formula (I-1), which comprises reacting a compound of formula (IV) with a compound of formula (V-1) or 10 (V-2) to give a compound of formula (VI-1); and reacting the compound of formula (VI-1) with a compound of formula (VII):


15



(IV)




(V-1)




(V-2)

20



(VI-1)



(VII)

25

wherein A, B, R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub> and R<sub>6</sub> are the same as defined in claim 1.


30

5. The process of claim 4, wherein the reaction of the compound of formula (IV) with the compound of formula (V-1) or (V-2) is carried out in the presence of a solvent selected from the group consisting of dichloromethane, acetone, acetonitrile and dimethylformamide, and a base 35 selected from the group consisting of triethylamine, N,N-dimethylaniline and pyridine.

- 89 -


6. A process for preparing a pyrimidine derivative compound of formula (I-2), which comprises: hydrolyzing a compound of formula (IV) at its 4-position to give a compound of formula (VIII); reacting the compound of formula (VIII) with a compound of formula (V-1) or (V-2) to give a compound of formula (IX); chlorinating the compound of formula (IX) at its 4-position to give a compound of formula (VI-2); and then reacting the compound of formula (VI-2) with a compound of formula (VII):

10




15

(IV)




(V-1)




(V-2)


20



(VI-2)




(VII)



(VIII)

25



(IX)

wherein A, B, R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub> and R<sub>6</sub> are the same as defined in claim 1.


30

7. The process of claim 6, where the reaction of the compound of formula (VIII) with the compound of formula (V-1) or (V-2) is carried out in the presence of a solvent selected from the group consisting of dichloromethane, acetone, acetonitrile and dimethylformamide, and a base selected from the group consisting of triethylamine, N,N-dimethylaniline and pyridine.


- 90 -

8. Pyrimidine derivative compounds of formulae (VI-1) and (VI-2):

5



(VI-1)




(VI-2)

10 wherein B, R<sub>4</sub> and R<sub>5</sub> are the same as defined in claim 1.


9. A process for preparing a compound of formula (VI-1), which comprises reacting a compound of formula (IV) with a compound of formula (V-1) or (V-2):

15


20



(IV)



(V-1)



(V-2)






wherein R<sub>4</sub>, R<sub>5</sub> and R<sub>6</sub> are the same as defined in claim 1.

10. The process of claim 9, wherein the reaction of 25 the compound of formula (IV) with the compound of formula (V-1) or (V-2) is carried out in the presence of a solvent selected from the group consisting of dichloromethane, acetone, acetonitrile and dimethylformamide, and a base selected from the group consisting of triethylamine, 30 N,N-dimethylaniline and pyridine.

11. A process for preparing a compound of formula (VI-2), which comprises: hydrolyzing a compound of formula (IV) at its 4-position to give a compound of 35 formula (VIII); reacting the compound of formula (VIII) with a compound of formula (V-1) or (V-2) to give a compound of formula (IX); and then chlorinating the compound of

- 91 -

formula(IX) at its 4-position:



wherein  $R_4$ ,  $R_5$  and  $R_6$  are the same as defined in claim 1.

12. The process of claim 11, wherein the reaction of  
20 the compound of formula (VIII) with the compound of formula  
(V-1) or (V-2) is carried out in the presence of a solvent  
selected from the group consisting of dichloromethane,  
acetone, acetonitrile and dimethylformamide, and a base  
selected from the group consisting of triethylamine,  
25 N,N-dimethylaniline and pyridine.

13. A pharmaceutical composition comprising a therapeutically effective amount of any of the pyrimidine derivative compounds of claim 1 and a pharmaceutically acceptable carrier.

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/AT 95/00105

## A. CLASSIFICATION OF SUBJECT MATTER

IPC<sup>6</sup>: C 07 D 239/42,401/04,409/14; A 61 K 31/505,31/38

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC<sup>6</sup>: C 07 D 239/42,401/04,409/14; A 61 K 31/505,31/38

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

AT

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

DARC

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A,P	Chemical Abstracts, Vol.122, No.23, 05 June 1995 (Columbus, Ohio, USA), page 1041, column 1, abstract No.290883s, SHIBATA, Masahiro et al. "Preparation of substituted pyrimidine derivatives as analgesics and antiinflammatory agents", & Jpn. Kokai Tokkyo Koho JP 07 53,527 [95 53,527].	1-13
A	Chemical Abstracts, Vol.120, No.8, 21 February 1994 (Columbus, Ohio, USA), page 654, column 2, abstract No.86474g, KIMURA, Isami et al. "Pyrimidine derivative for treatment of ulcerative colitis", & Jpn. Kokai Tokkyo Koho JP 05,262,747 [93,262,747].	1-13
A	Chemical Abstracts, Vol.118, No.10, 08 March 1993 (Columbus, Ohio, USA), page 457, column 1, abstract No.87674z, TAKEDA, Dennai et al. "Oral preparations containing antiallergy pyrimidine derivative", & Jpn. Kokai Tokkyo Koho JP 04,305,526 [92,305,526]. —	1-13

 Further documents are listed in the continuation of Box C. See patent family annex.

## \* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "&" document member of the same patent family

Date of the actual completion of the international search 20 October 1995 (20.10.95)	Date of mailing of the international search report 07 November 1995 (07.11.95)
Name and mailing address of the ISA/ AT AUSTRIAN PATENT OFFICE Kohlmarkt 8-10 A-1014 Vienna Facsimile No. 1/53424/535	Authorized officer Brus e.h. Telephone No. 1/5337058/32

BEST AVAILABLE COPY